Field of the Invention
Embodiments of the invention relate generally to medical connectors through which fluids flow, and in particular, to self-sealing medical connectors.
Description of the Related Art
Closeable medical connectors or valves are useful in the administration of fluids in hospital and medical settings. They are often used to selectively open and close fluid pathways, and in particular for use in treating patients.
Some embodiments disclosed herein relate to a closed, patient access system which can automatically reseal after administering fluid, medicaments, or other suitable substances (hereinafter, collectively referred to as “fluid”) using a medical implement that connects or communicates with the system. A two-way valve can be employed, utilizing a reusable seal that may be repeatedly opened. The valve can facilitate the transfer of fluid, particularly liquid, while maintaining sterility. Before and after use, the valve can be swabbed in a conventional manner with a suitable substance to maintain sterility.
Some embodiments disclosed herein relate to a medical connector having transparent features that allow direct optical view of the fluid, or medicament, or bodily fluid, being transferred through the medical connector. In some embodiments, the connector includes a body member having a transparent wall with smooth inner and outer surfaces to provide a relatively distortion free optical view of the fluid level and fluid flow transferred through the connector. In some embodiments, the connector further includes a valve member and a base member having a support.
Some embodiments disclosed herein relate to a medical connector having a backflow resistance module configured to prevent fluid from being drawn into the connector when a backflow inducing event occurs (e.g., a syringe rebound, a syringe disconnection, etc.). In some embodiments, the backflow resistance module can include a variable volume chamber configured to change in volume in response to a backflow-inducing event and a check valve configured to resist backflow. In some embodiments, the medical connector can include a fluid diverter configured to direct fluid flowing through the medical connector into the variable volume chamber to prevent fluid stagnation therein. In some embodiments, the medical connector includes a body member, a base member, a seal member, a support member, and a valve member.
In accordance with another embodiment, a medical connector for use in a fluid pathway comprises a first portion having a first end and a second end, the first portion being substantially transparent, and a second portion having a first end and a second end, the first end of the second portion adjacent the second end of the first portion. The connector includes a first valve member having a first end and a second end, the first valve member disposed substantially within the first portion, wherein a substantially straight fluid flow path within the first portion and the second portion is visible through an external surface of the first portion and the second portion.
In accordance with another embodiment, a medical connector for use in a fluid pathway comprises a substantially transparent housing having a proximal end with a proximal opening and a distal end with a distal opening, and a cavity extending therebetween. The connector includes a substantially transparent valve member disposed substantially within the housing, and having a proximal end that substantially fills the housing proximal opening. The valve includes a proximal opening that is biased closed to obstruct fluid flow therethrough. The valve member is configured to selectively seal the housing proximal opening and to obstruct fluid communication between the housing proximal end and the housing distal end when the valve member is provided in a first position and to facilitate fluid communication between the housing proximal end and the housing distal end when the valve member is provided in a second position. The connector includes a support member configured to be substantially transparent and received within the valve member. The support includes an inner conduit that extends from adjacent a proximal tip portion having at least one opening that extends through the support member to the inner conduit to a distal end of the support member. The support member selectively facilitates fluid communication between the housing proximal end and the housing distal end. In some embodiments, the fluid communication between the housing proximal end and the housing distal end is established when the tip portion and at least a portion of the at least one opening protrude proximally through the valve proximal opening. A fluid flow path facilitates the fluid communication between the housing proximal end and the housing distal end and is visible through at least a portion of each of the transparent housing, the transparent valve member, and the transparent support member.
In accordance with another embodiment, a method of transferring fluid from a first medical implement to a second medical implement comprises providing a medical connector having a transparent housing with a proximal end and a proximal opening and a distal end and a distal opening. The connector includes a transparent flexible valve member disposed substantially within a cavity of the housing and with a valve member proximal end that substantially fills a portion of the cavity proximate the proximal opening. The valve includes an aperture adjacent the valve member proximal end. The connector further includes a transparent substantially hollow rigid support member configured to be received within the valve member and having an opening adjacent a proximal end of the support member. The flexible valve member is positionable between a first position that prevents fluid communication through the valve aperture and a second position that facilitates fluid communication through the valve aperture. The method includes coupling the housing proximal end to a first medical implement wherein a distal end of the first medical implement enters the housing proximal opening and may further include coupling the housing distal end to a second medical implement. The method further includes displacing the valve member by distally delivering the first medical implement within the housing and pushing a proximal end of the support member through the valve aperture, establishing fluid communication between the first medical implement and the second medical implement. As fluid flows between the first medical implement and the second medical implement, the fluid communication is optically visible through at least a portion of each of the transparent housing, the transparent valve member, and the transparent support.
In accordance with another embodiment, a medical connector comprises a housing configured to be substantially transparent and having a proximal opening adjacent a proximal end and a distal opening adjacent a distal end, and a fluid communication cavity extending therebetween. A first valve member can be disposed substantially within the housing and configured to be substantially transparent, and includes a proximal opening that is biased closed to obstruct fluid flow therethrough. The valve member is configured to obstruct fluid communication between the housing proximal end and the housing distal end when the valve member is provided in a first position and to facilitate fluid communication between the housing proximal end and the housing distal end when the valve member is provided in a second position. The connector includes a support member configured to be substantially transparent and to be received within the valve member, and having an inner conduit that extends from adjacent a proximal tip portion having at least one opening that extends through the support member to the inner conduit to a distal end of the support member. The support is configured to selectively facilitate fluid communication between the housing proximal end and the housing distal end, wherein the fluid communication between the housing proximal end and the housing distal end is established when the tip portion and at least a portion of the opening protrude through the valve proximal opening. The connector further includes a second valve member disposed substantially within the housing and configured to be substantially transparent, and having a proximal opening and a distal opening, and a wall member extending between the proximal opening and the distal opening. The wall deflects when a pressure differential between a proximal side of the second valve distal opening and a distal side of the second valve distal opening exceeds a predetermined threshold. A fluid flow path establishing the fluid communication between the housing proximal end and the housing distal end is visible through at least a portion of each of the transparent housing, the transparent valve member, and the transparent support member.
Certain embodiments of the invention will now be discussed in detail with reference to the following figures. These figures are provided for illustrative purposes only, and embodiments of the invention are not limited to the subject matter illustrated in the figures.
The following detailed description is now directed to certain specific embodiments of the disclosure. In this description, reference is made to the drawings wherein like parts are designated with like numerals throughout the description and the drawings.
A variety of closing mechanisms are shown for closing one or more end portions of the needlefree connectors described herein. These closing mechanisms can function to substantially prevent and/or impede fluid from passing through the end portions of the connector when the closing mechanisms or valves are in a closed position. When the closing mechanisms are in an open position, such as when the connector is engaged with a needleless syringe or other medical connector, fluid can be permitted to pass through one or more end portions of the connectors. As used herein, terms such as “closed” or “sealed” and variants thereof should be understood to refer to obstructions or barriers to fluid flow. These terms should not be understood to require that a particular structure or configuration achieves a complete fluid closure in all circumstances.
In some aspects of the embodiments disclosed herein, a variety of structures and functions are shown and described for controlling and observing the fluid flow of medicaments or the like through medical connectors described herein. For example, it may be desirable to visually observe in real-time the fluid flow and/or the fluid position through the medical connector. Direct optical sight of the internal fluid can readily identify fluid leaks at sealing surfaces, contamination, residual fluids, blood, or the like, and minimize the risk of fouling the connector and thus requiring removal and replacement. As used herein, the terms “transparent” or “clear” and variants thereof should be understood to refer to the ability to substantially observe or see through a material or an object. These terms should not be understood to require that a particular structure or configuration achieves a completely undistorted view through the material or object in all circumstances.
In some aspects of the embodiments disclosed herein, a variety of structures are shown and described for controlling the flow of fluid and the passage of particles at a proximal inlet, or proximal opening, of a medical connector. A reusable medical connector requires repeated sterilization, for example, by conventional swabbing before inserting or after removing a medical implement to disinfect the silicone seal surface. Each swab sterilization procedure risks introducing contaminants to the internal portion, or cavity, of the medical connector to create a non-sterile condition, potentially inhibiting the purpose of the intended sterilization of the connector.
In some aspects of embodiments disclosed herein, a variety of structures are shown and described for controlling the flow of fluid inside a connector. These fluid control valves or mechanisms can facilitate the control of potentially undesirable fluid movement out of or into the connector. For example, it may be desirable to prevent, inhibit, or diminish negative flow or fluid ingress into the connector. As used herein, negative flow, retrograde flow, backflow, ingress flow, and related terms are used in accordance with their customary meanings in the medical connector field. In some cases, these terms refer to the flow of fluid into the connector due to an increase or effective increase in the internal volume of the fluid space within the connector, or due to an external draw or removal of fluid (such as by withdrawal of a portion of a medical implement, e.g. a syringe, or the like, previously inserted into the connector), or due to an external source of fluid pressure in a general retrograde direction, such as that caused by a patient's cough, or by an increase in a patient's blood pressure, or by disturbances in a fluid source (e.g., fluid volume in an IV bag diminishing or “running dry”), etc. Negative flow generally occurs in a direction generally opposite from or opposed to an intended flow of fluid into a patient.
One example of a source of negative flow occurs when a medical implement, such as a syringe, is removed from the proximal end, also referred to herein as the first or female end of the connector. As the syringe is removed, the fluid holding space inside the connector may increase. When that fluid space is in communication with a patient's fluid line catheter, the increase in fluid space inside the connector may draw fluid from the catheter into the connector from the distal end, also referred to herein as second or male end of the connector. This can be disadvantageous because negative flow can thereby draw blood from the patient into the opposite, or downstream, or patient, end of the catheter line. Such blood in the line can clot or otherwise foul the line, possibly requiring premature replacement and reinsertion of the catheter line, the connector, and/or other medical implements. Other sources of negative flow can be caused by a pump machine or a manual syringe due to springback of compressed rubber, or sealing, components of the pump or syringe that creates a void upon release of pressure that is capable of being filled with fluid from the catheter.
Some embodiments can generally provide optical clarity of the fluid flow within the internal cavities of a medical connector. Some embodiments can generally eliminate, diminish, minimize, or control the risk of contamination during sterilization of the connector ends. Some embodiments can generally eliminate, diminish, minimize, or control the effect of some or all sources of negative flow. Although the functionality of some of the embodiments disclosed herein is discussed in connection with a single source of negative flow (e.g., syringe rebound), it should be understood that many sources of negative flow can be eliminated, diminished, minimized, or controlled in similar or identical ways.
The syringe 200 illustrated in
The term “proximal” is used herein to denote the end of the connector 10 at or near the body member 20 end of the connector. The term “distal” is used to denote the opposite end of the connector, e.g., the end of the connector 10 at or near the end of the base member 90. In the illustrated embodiment, the proximal end is configured as a female end and the distal end is configured as a male end. Any of the end portions, fittings, or other aspects of the connector 10 can be configured to accommodate any standard medical connector or implement, and can be configured to conform with ANSI (American National Standards Institute, Washington, D.C.) or other applicable standards. The term “medical implement” is used herein to denote any medical device commonly used in the medical field that can be connected or joined with any embodiments of the connectors disclosed herein. Examples of medical implements that are contemplated include, without limitation, tubing, luers, conduits, syringes, intravenous devices (both peripheral and central lines), closable male luer connectors (both integrally formed with a syringe or independent connectors), pumps, piggyback lines, and other components which can be used in connection with a medical valve or connector.
In the illustrated embodiment, the body member 20 and the base member 90 can be assembled together to form a housing that substantially encloses the seal member 60, or first valve member, and the support member 94. In one embodiment, the distal end of the body 20 can overlap the proximal end of the base 90. The support member 94 can include an elongate portion 118, or blunt cannula, or rigid support, which protrudes proximally and can be configured to receive the seal 60. The seal 60 can move axially, or longitudinally in a proximal to distal or distal to proximal direction about the elongate portion 118 within the housing formed by the body 20 and the base 90. The connector 10 can include a valve mechanism with a dynamic seal capability that is established between the engagement of the seal 60 and the elongate portion 118 that can have an open position and a closed position. The connector proximal end can receive a medical implement which can distally urge and compress the seal 60 about the elongate portion 118 to open the valve mechanism of the connector 10 and establish a fluid flow path through a radial opening 100 in the elongate portion 118. The fluid flow path can be directed from the medical implement into the elongate portion 118, through the base 20, and out an opening adjacent the distal end 124. The valve mechanism can be in a closed position when the seal 60 is extended over and covers, or encapsulates, the substantially full length of the elongate portion 118. The features of the body member 20, the seal member 60, the base member 90, the support member 94, the elongate portion 118, and the assembly therebetween are described in further detail below.
In some embodiments, the body member 20 can include a proximal end 22, or first end, and a distal end 24, or second end, with the body 20 extending therebetween. The body includes an outer surface 46 and an inner surface 44. The body can be transparent, or substantially transparent, such that objects or things positioned on the inside, or opposing side, of the body 20 are visible when viewed through the material of the body 20. The transparent body 20 facilitates viewing of the fluid medicament being delivered to, or bodily fluid being extracted from, the patient through the connector 10. In some embodiments, a substantially straight fluid flow path within the body 20 and the base 90 is visible through the external surface of the body and the base.
The proximal end 22 can have outwardly extending external threads 26 so that the connector 10 can be configured to couple, or be threadingly joined, to a male end of a standard luer connector or other suitable medical implements. In some embodiments, the outer surface 46 of the proximal end portion 22 can be smooth and generally cylindrical.
The body member 20 can have an annular ridge or protrusion 50 formed around an outside surface 46 of the body member 20 adjacent to the proximal end 22 of the body member 20. The protrusion 50 can be configured to engage a threaded collar or shroud (not shown) that may be included on a luer lock type syringe coupled onto the external threads 26, to prevent or inhibit over insertion of the syringe into the connector.
The body 20 can further include a proximal opening 28 disposed at the proximal end 22, and a distal opening 30 disposed at the distal end 24. In some embodiments, the proximal opening 28 is smaller than the distal opening 30. The body 20 can include a cavity 42, or passageway, in the internal portion of the body, and extending from the proximal end 22 to the distal end 24. The cavity 42 defines a passageway extending between the proximal opening 28 and the distal opening 30, such that an opening extends all the way through a longitudinal length of the body 20. The transparent body 20 material provides a clear optical view of the internal features of the body 20. For example, as illustrated in
In some embodiments, the cavity 42 is generally round, or cylindrical, and can include a plurality of different diameters at different longitudinal locations of the body 22. For example, in one embodiment, the proximal inner diameter of the body 20, or the cavity 42, can have a first diameter at the proximal end and transition at a predetermined longitudinal location to a second, larger diameter for the remaining longitudinal length of the body 20 to the distal end 24. In some embodiments, the inner diameter of the cavity 42 can have more than two diameters. In some embodiments, the inner diameter of the cavity 42 can be tapered for at least a portion of the longitudinal length. In some embodiments, the cavity 42 can include a plurality of different sized tapered portions, having different angled surfaces. In some embodiments, the cavity can have curved internal surfaces extending longitudinally. In some embodiments, the change in diameter can be smooth and blended to provide optical clarity through the transparent body wall. In some embodiments, the change in diameters can be abrupt and/or discontinuous with sharp or semi-sharp changes in surface geometry and provide transparent optical clarity of the internal features of the connector. In some embodiments, the cross-section geometry of the cavity 42, normal to the longitudinal axis, can have a shape other than circular or round, e.g. oval, polygonal, or the like, with corresponding changes in internal cross sectional areas along the longitudinal axis as described in detail above.
With continued reference to
The smooth internal surface 44 can provide an area, or a volume, for the seal member 60 to collapse into when the seal compresses longitudinally. The smooth surface area also provides a radially limiting contact surface for the seal member 60 when the seal moves, or expands, radially outward within the housing.
The proximal portion of the cavity 42 can include a radial projection 36, or a shoulder, or an inward transition, or an inward protrusion, which defines a change in the inner diameter of the body 20, or the cavity 42. The shoulder 36 defines the transition from a larger distal inner diameter to a smaller proximal inner diameter of the cavity 42. The transition of the shoulder can be angled, or tapered, relative to the longitudinal axis of the body 20. The shoulder 36 provides a physical stop, or retention means, for a portion of the seal member 60 in the connector 10 assembly, as illustrated in
In the illustrated embodiment of
The annular channel 38, or groove, extends around the inner surface 44 circumference of the cavity 42 adjacent the distal end 24, and can be positioned distal to the channels 40. The annular groove 38 can be configured to receive an annular protrusion 96 disposed about the base member 90 outer surface, which is described in greater detail below. The annular channel 38 lies substantially about a plane that is generally normal to the body 20 longitudinal axis. The annular channel 38 and the annular protrusion 96 can be configured to join, or mate, or engage, one another to provide a snap-fit type connection between the body member 20 and the base member 90. In this configuration, when the body member 20 has been joined with the base member 90 (as is illustrated in
In some embodiments, at least a portion of the longitudinal length of the hollow body 20 has a constant thickness wall. A constant wall thickness can provide a minimally distorted view of the interior cavity 42. In some embodiments, the body 20 can have a constant wall thickness for the full longitudinal length. In some embodiments, the various longitudinal portions include differing wall thicknesses with minimal effect on the optical clarity of the interior volume of the cavity 42.
The body member 20 and any other components or features of the connector 10 can be constructed from any of a number of suitable materials. For example, the body member 20 or any other suitable components or features of the connector 10 can be constructed from a relatively rigid transparent material, such as polycarbonate, glassed-filled GE Valox 420, polypropylene, other polymeric material, or the like, or any combination thereof. The body member 20, or any other suitable components or features of the connector 10, can also be constructed of a transparent hydrophobic material, such as Bayer Makrolon, or any other similar or suitable material. One or more components of the connector 10 or any other connector disclosed herein can include a suitable antimicrobial agent in any appropriate form, such as a component coating, as a part of the component matrix, or in any other suitable manner. In some embodiments, the antimicrobial agent may leach from or off one or more of the components during use or over time. In some embodiments, the antimicrobial agent can include a silver ion.
In some embodiments, as in the illustrated embodiment, the seal proximal end portion 62 can include the lip portion 66, or annular protrusion, which can have various geometric shapes formed thereon, e.g. rectangular, square, radiused, chamfered, or the like, or any combination thereof. The lip 66 can define the outermost radial portion of the seal proximal flange 64. The lip 66 can be a sealing feature of the proximal end 62, and can establish a sealing interface with the mating surface of the body neck 32.
With reference to
The seal proximal flange 64 can include the flat, or substantially flat, face 63 that encloses the proximal end 62 and can be generally perpendicular to the longitudinal axis of the seal. The slit 70, or seal first end opening, can be disposed in the proximal face 63. The proximal flange face 63 can establish the proximal most surface of the seal 60. The proximal flange face 63 can be positioned adjacent the proximal end 22 of the body 20 such that the seal flange face 63 and the body proximal flange 48 are substantially co-planar. In some embodiments, the face 63 can be any geometric shape, e.g. spherical, parabolic, or the like, or any combination thereof, rather than substantially flat.
The seal 60 proximal end 62 can include the collar 72, or prongs, that protrude radially outward from the outer surface of the seal. The collar 72 can extend around the full circumference of the seal 60, or a portion thereof, e.g. one, two, three, or four, or more, individual prong portions of a collar spaced about the circumference of the seal 60, for example, equally spaced around the circumference, or the like. Controlling the number of projections forming the collar 72 allows manipulation of the force required to open the connector. The gaps, or areas of thinner thickness, facilitate movement of the seal 60 along the elongate member 118 as the thicker projections resist expansion around the elongate member 118.
The collar 72 outer diameter can generally be smaller than the internal diameter of the middle portion of the body 20, but generally larger than the internal diameter of the neck 32, proximal opening 28, and internal cavity 42 adjacent the proximal end 22 of the body 20. The collar 72 can be configured to engage the body shoulder 36 and limit the axial extension or movement of the seal proximal end flange face 63. The collar 72, seal 60, and body 20 can be configured to position the flange face 63 at a substantially coplanar position relative the body proximal end face 48. The seal 60 and the body 20 can be configured to consistently and repeatedly align the seal proximal face 63 with the body end face 48 when the seal 60 returns to a biased extended length. The collar 72 distal surface can have a geometry that corresponds to the geometry of the shoulder 36, e.g. angled, radius, chamfered, or the like, or any combination thereof.
The distal end 78 of the seal member 60 can include an opening 82. In some embodiments, the opening 82 can be configured to receive the support member 94. In some embodiments, the distal end 78 further includes an outwardly extending flange 74 extending around or substantially around the seal member 60. The flange 74 can facilitate placement of the seal member 60 within the internal cavity of the body member 20 in some embodiments. In some embodiments, the seal distal flange 74 engages a support portion 94 disposed about the base 90.
The seal member 60 can be configured so that the slit 70, or first end opening, is biased to a closed position, so as to substantially prevent or inhibit liquid from flowing through the slit 70 formed in the seal member 60. Additionally, in some embodiments, as will be described in greater detail below, the slit 70 can be opened by delivering an elongate member, needle, protrusion, or the like, through the slit to separate the two biased side edges of the slit. In some embodiments, the slit 70 can be opened by distally compressing the seal member 60 proximal end 62 toward the seal distal end 78, wherein the seal proximal end 62 may slide over the elongate member 118 of the support member 94, causing at least a portion of the proximal end portion of the elongate member 118 to penetrate and pass through the slit 70. In some embodiments, the slit 70 can be configured to open without the support member 94 penetrating therethrough.
The seal member 60 can have a tapered resilient body portion 84 having a varied geometry, including bellows, convolutes, generally accordion-like, generally wave-like, generally alternating, or generally undulating contour shape configured to facilitate resilient compression and expansion of the seal member 60 as axial forces are applied to and removed from, respectively, the proximal end portion 62 of the seal member 60. In some embodiments, the body portion 84 can include a series of generally circular or o-ring shaped structures integrally formed together or separately formed and bonded together, or one or more groove structures oriented generally transverse to the axial direction of compression and expansion. These structures and contours can vary in diameter or cross-sectional shape and/or size. In some embodiments, the structures or contours can extend alternately generally inwardly and outwardly in a direction substantially perpendicular to the longitudinal axis of the seal member 60, as shown, for example, in
In some embodiments, the inside surface of the seal body 84 can approximately match the outside surface of the seal body 84 such that the inside surface of the seal body 84 can have the structure or contour described elsewhere herein. In some embodiments, the seal 60 convolutes 80 can have a substantially constant wall thickness. In some embodiments, the inside surface of the seal body 84 can generally extend radially inward when the corresponding portion of the outer surface of the seal body 84 extends radially outward, and the inside surface of the seal body 84 can generally extend radially outward when the corresponding portion of the outer surface extends radially inward. Thus, the seal body 84 can comprise a series of bulges, wherein the seal body 84 wall thickness alternates between thick and thin regions, as shown, for example, in
The seal body 84 can have a generally consistent cross-sectional shape or size along the longitudinal length thereof, or the cross-sectional shape or size of the seal body 84 can vary along at least a portion of the longitudinal length thereof. In some embodiments, the shape of the inside of the seal body 84 can approximately match the outside surface of the elongate portion 118 of the support member 94. In some embodiments, the seal body 84 comprises a distal section 84a having a generally conical interior and exterior shape, and a proximal section 84b having a generally cylindrical interior and exterior shape. Many variations are possible, e.g. a cylindrical distal section and a conical proximal section, more than two sections having different geometric shapes, or the like.
The seal member 60 can be configured so that the seal body 84 is biased to an initial longitudinally, or axially, expanded first position, as illustrated in
The seal member 60, the proximal end portion 62 of the seal member 60, and the lip portion 66 can be integrally formed or can be separately formed and adhered or otherwise joined together using adhesive or any suitable material or method. In some embodiments, the seal member 60 or any other embodiment of a seal or seal member disclosed herein and any of the components or features thereof can be constructed from a number of different suitable materials, including silicone-based deformable materials, rubbers, or other suitable materials. Silicone-based deformable materials are among those that form fluid-tight closures with plastics and other rigid polymeric materials.
The seal member 60 or any other seal member disclosed herein can be formed from one, two, or more different materials. In some embodiments, different portions of the seal member 60 can be formed from different materials. For example, the seal member 60 can have a spring formed therein, not shown, to provide some or all of the restoring force desired to bias the seal member 60 to the closed position. The spring can be formed from a metal such as steel, plastic, or any other suitable rigid or pliable material, and can form the core of the seal member 60 such that the silicone rubber or other pliable sealing material encapsulates the spring. In some embodiments, the seal member 60 can be constructed just from a resilient or elastomeric material. Also by way of example, seal member 60 may include a resilient main body portion and a separately formed resilient proximal end portion. The separate pieces may be configured to engage each other, such as for example, by coupling to a guide member with a first end configured for attachment to the proximal end portion and a second end configured for attachment to the main body portion. The guide member may be manufactured from a more rigid material than used in either or both of the main body portion and the proximal end portion.
With continued reference to
In some embodiments, the one or more components of the illustrated base 90 and support member 94 can be separately formed and attached to one another via an adhesive, sonic welding, snap fit, or other suitable coupling manner, or any combination thereof. For example, the transparent elongate portion 118 and the transparent support portion 94 can be separately formed and attached by, for example, sonic welding. For example, the elongate portion 118 may be separately formed from the base member 90, and the elongate portion 118 and/or any other portion can be configured to move within the connector during use. For example, shroud 98 can be separately formed and later attached to base 90. In some embodiments, the entire base 90 can be integrally formed as a one-piece unit, to include the elongate portion 118, the support member 94, the shroud 98, and male protrusion tip 116.
In the illustrated embodiment, the at least one radial opening 100 is disposed adjacent the tip portion 92, or the proximal end 95, and can be in fluid communication with the conduit 102, or fluid passageway, extending generally axially, or longitudinally, through the base 90 to the distal opening 114. The conduit 102 can be defined by an inner surface 106 of the elongate portion 118. The radial opening can be a longitudinally oriented oval shape, or any other geometric shape in any other direction, e.g. round, rectangular, square, or the like. In some embodiments, the tip portion 92 can include two radial openings 100 disposed circumferentially substantially 180 degrees from one another. The fluid passageway 102 can extend through a substantial portion of the elongate portion 118, the support member 94, and the male tip protrusion 116. In some embodiments, the opening can be disposed at the proximal end of the tip 110.
As illustrated in
The elongate portion 118 can include a lubricant applied to the outer surface 104 to facilitate the sliding, or slidable, engagement with the inner diameter surfaces of the seal 60. The lubricant can provide for an ease of sliding the seal proximal end 62 in a distal direction onto the expanding diameter of the tapered geometry of the elongate portion 118. The lubricant can include any suitable lubricant, e.g. silicone, or the like. In some embodiments, the roughened outer surface 104 can provide control, or resistance, to the lubricated sliding engagement between the outer surface 104 and inner diameter surface of the seal 60. The resistance, or control, can prevent excessive compression or too rapid of a compression or expansion of the seal member 60 during functional operation, or connection of a medical implement to the connector 10.
The proximal tip portion 92 can have a generally tapered, or generally conical, outer surface. In some embodiments, the tip portion 92 can be generally cylindrical. The elongate portion 118 can be configured so that the proximal tip portion 92 comprises a cross-sectional area that is significantly less than the cross-sectional area of the support portion 94. In some embodiments, the proximal tip portion 92 can be configured so that the proximal end portion 62 of the seal 60 can be distally retracted (e.g., repositioned from the expanded or initial position to the compressed position) relative to the proximal tip portion 92 of the support 94 without significant drag or resistance from the support member 94 or the elongate portion 118. In some embodiments, the proximal tip portion 92 has a sharp or rounded tip 110 configured to penetrate through the slit 70 formed in the seal 60 proximal flange face 63. In some embodiments, the tip 110 is integrally formed with the tip portion 92 and the rest of the elongate portion 118. In some embodiments, the proximal end of the elongate portion 118 includes a hole positioned at its proximal tip and the passageway 102 may extend from the opening 114 to the opening at the tip. In some such embodiments, it may be advantageous to include a seal 60 with an opening that is molded in the open position to facilitate passage of the seal 60 over the open tip 110.
In the assembled configuration, the seal 60 can be supported by the support 94 so that the elongate portion 118 is received within the opening 82 formed within the seal 60. The seal member 60 can thus be supported within the body member 20 and the base member 90. The body 20 and the base 90 can be joined together to provide the rigid housing that substantially encapsulates the seal 60 and the support 94 in the internal cavity 42.
With continued reference to
The base 90 can have the male tip protrusion 116 projecting distally therefrom. The male tip protrusion 116 distal end can define an opening 114 through the male protrusion that can be in fluid communication with the cavity 42 formed inside the body 20 and base 90. In some embodiments, as illustrated, the male tip protrusion 116 can be substantially open to fluid communication in both the open and closed positions of the valve. Additionally, a shroud 98 may include radially outward protrusions or other features (not shown) thereon designed to enhance the grip of the connector 10 and internal threads 128 formed on an inside surface 130 of the shroud 98. The base member 90 can be configured to conform with ANSI standards for medical connectors.
As mentioned, the base 90, including the elongate member 118 and the support 94, can be formed from the same type of rigid materials as can be used to form the body member 20. In some embodiments, for example, the base member 90 can be formed from a semi-rigid or even more flexible material than used for the body member 20, or other components of the connector 10. In some embodiments, the base 90 (and any other embodiment of a base or support member of any other connector disclosed herein) can be formed integrally with the elongate member 118 and the support 94 (or any other embodiment of a base member of any other connector disclosed herein), or can be formed separately and thereafter joined with the support member or the elongate member 118. In addition, in some embodiments, portions of the base 90 may be formed integral with the body 20. For example, the body 20 may include the shroud 98 and the base 90 may fit substantially within the body 20.
The assembly of the connector 10 will now be described. In some embodiments, the connector 10 can be assembled by slidingly coupling the seal 60 onto the base 90 by inserting the proximal end, or tip portion 92 end, of the elongate portion 118 into the seal distal opening 82 so that the elongate portion 118 receives the seal 60. The support annular channel 108 can receive the seal distal end 78, and the seal distal face can engage the seal step 122. The elongate portion 118 or the inner surface of the seal opening 82, or both, can be coated with a lubricant prior to assembling the seal 60 onto the elongate portion 118 to facilitate sliding engagement between one another. The seal proximal end 62 and the elongate portion 118 can be inserted into the body 20 distal opening 30. The seal and elongate portion can proximally engage the body cavity 42.
The seal 60 can be configured to have a minimal internal volume, or gap, between the elongate member proximal tip 92 and the seal proximal flange face 63 in the assembled configuration. Particularly, the internal volume adjacent the proximal end 62 can be minimized. The minimal internal volume, or gap, can decrease the retrograde, or backflow, effects of syringe removal from the connector 10. The backflow effect can occur because of the withdrawal of the volume of the elongate portion 118 tip 110 from the slit 70, whereby the fluid is drawn into the volume previously occupied by the tip 110.
The body 20 and base 90 are lockingly engaged longitudinally, or axially, by the body annular channel 38 receiving and engaging, in a snap fit type manner, the base annular protrusion 96. The body 20 and base 90 are lockingly engaged circumferentially by the body channels 40 receiving and engaging the base protrusions 112. The body member 20 and the base member 90 can be further coupled together with adhesive, plastic or sonic or laser welds, snap, interference, or press-fit features, or by using any other suitable coupling features or methods. In some embodiments, the body member 20 and the base member 90 can be coupled together using sonic welds having a substantially triangular shape, although other shapes may also be suitable.
Upon assembly of the connector 10, the seal 60 is in an extended, closed valve position. In the extended position, the seal 60 is generally still compressed because of the retaining contact between the seal prongs 72 and the body shoulder 36. In some embodiments, the seal 60 can be fully expanded when making contact with the shoulder 36 and having the proximal flange face flush to the body proximal face 34. The connector 10 can include a flow path that enters at the body 20 proximal opening 28 into the body cavity 42. Fluid flow proceeds from the cavity 42 into and through the radial openings 100 disposed at the proximal tip portion 92 of the elongate portion 118. In some embodiments, fluid does not enter the cavity 42 directly, as an inserted medical implement, such as a syringe, can directly and sealingly engage the seal proximal face 63, and distally depress the seal 60 proximal face to establish fluid communication with the radial opening 100 of the elongate member 118 and the conduit 102. Thus, the fluid would flow from the syringe into the radial opening 100 and conduit 102. The internal blunt cannula, or elongate member 118, can create a unique dedicated internal fluid path such that at no time can the body 20, the outer surface of the seal 60, or the outside of the syringe come in contact with the fluid or the fluid path. The sealing engagement between the syringe and the seal proximal flange face 63 defines a safe and effective microbial barrier that reduces bacteria transfer into the fluid flow path. The sealing engagement can protect the vascular access device against intraluminal bacterial contamination.
The conduit 102 and seal 60 can combine to define an ultra low residual volume, or deadspace, which provides several advantageous effects. The ultra low residual volume establishes a neutral displacement that can eliminate blood or fluid backflow into the catheter when the upstream medical implement is disconnected from the connector. A saline flush can be performed to provide for reuse following blood sampling or administration of fluids with normal saline or in accordance with facility protocol, facilitated by little or no blood backflow induced by the connector. The neutral displacement also allows for effective flushing after using the connector with blood, to flush the blood out of the connector flow path in the conduit 102. Neutral displacement also can preclude the need for a clamping sequence of the conduit 212 that enters the patient. Additionally, the lack of backflow can eliminate the educational burden and risk of error for medical personnel. The minimal volume to flush the connector to remove blood or medicament fluid from the from connector 10 can allow continued use of the connector 10 without having to remove or replace the connector. This can reduce the amount of manipulation of the connector 10, where removal and replacement of the connector 10 can increase the risk of bacterial contamination.
The fluid can flow through the elongate portion 118, in conduit 102, to the distal opening 114 of the male protrusion tip 116. The base 90 distal end 124 can be coupled to a distal, or downstream, medical implement that is coupled to the luer fitting and threads 128 on the inside surface 130 of the shroud 98. Thus, the fluid can exit the connector 10 at the distal opening 114 and continue into the downstream, or distal, medical implement. The substantially transparent body 20, seal 60, and elongate portion 118 can provide a substantially clear view of the fluid flow within the connector 10 during medicament delivery or bodily fluid extraction. Visual awareness, or inspection, of potential contamination of the plurality of cavities in the connector 10 can reduce the risk of potential harm to the patient, e.g. bacterial growth or biofilm due to stagnant or residual fluid or the like, by prompting immediate cleaning or flushing of the connector 10 or removal and replacement of the connector 10. For example, the visual inspection can prevent catheter related bloodstream infections such as catheter sepsis that can be caused by residual blood in the needlefree connector 10.
The connector 10 valve mechanism is closed when the seal 60 extends proximally over, and encompasses, the elongate portion 118. In some embodiments, the inward bias of the adjacent edge surfaces of the seal slit 70 cause the edges surfaces to coapt and prevent fluid or particulate access to the internal volume of the seal 60, and thus to the fluid flow path of the radial openings 100. The valve mechanism of the connector 10 can be urged into an open position by distally displacing the seal 60 to slide in a distal direction. The proximal end, or first end, of the seal 60 can be positionable between a first position and a second position. The proximal portion, or first end, of the elongate portion 118, can be disposed substantially within the proximal end of the seal 60 when the seal is in the first position. The elongate portion 118 can protrude through the seal slit 70 as the seal proximal end 63 moves distal of the tip portion 92. Upon such distal movement, the proximal portion, or first end, of the elongate portion 118 can be disposed substantially outside of the proximal end of the seal 60 when the seal is in the second position. The fluid flow path is open when the seal proximal face 63 material, and the slit 70, have moved distally past the radial openings 100 to expose the radial openings 100 to the internal surface of the syringe. The radial openings 100, or apertures, facilitate fluid communication to the fluid flow path when the valve is in the second position. When the syringe distally urging implement, or force, is relieved from the seal 60, the resilient bias of the seal extends, or decompresses, or expands, the seal to an increased longitudinal length whereby the seal slit 70, or septum, encompasses the radial opening 100 and the tip portion 92 to close the connector 10 valve mechanism.
Some embodiments of the connector 10 can be formed so that there is very little dead space volume, or a neutral displacement as discussed above, within the connector 10 as compared to the volume range of a typical bolus of fluid administered to a target patient population. Thus, the volume of fluid entering into the connector 10 can be substantially equivalent to the volume of fluid leaving the connector 10. Further, the total equivalent fluid volume of the connector 10 can be very small, e.g. 0.02 cc, 0.04 cc, or the like, such that the volume of fluid flowing through the system in order to place the valve in fluid communication with a medical implement such as a syringe can be very close or equal to zero. A small volume of dead space within the fluid flow path reduces, or mitigates, the vacuum effect that generates negative flow when the syringe is removed from the connector 10. The volume of dead space can be limited to the air gap in the inner volume of the proximal end 62 of the seal 60. The small volume between the tip 110 and the seal proximal face 63 advantageously can create minimal, if any at all, negative flow effects from the catheter into the distal end of the connector 10.
In some embodiments, the support member may be substantially shorter, such that it does not extend into, through and/or near the proximal end of the seal. In some embodiments of the connector 10, there is no support member at all. A seal member can be configured to open without a penetrating support member or without a support member at all, such as when a seal member is made in a naturally open position that is forced to close by a smaller-diameter housing, or when a seal member is attached to the proximal region of the housing, etc. Alternatively, the support member may not be rigidly fixed in the housing. Rather, it may be held in the housing via a resilient seal and may translate longitudinally upon insertion of a medical device into the proximal end.
With reference to the illustrated embodiments of
The syringe 200 illustrated in
In order to inject all or substantially all of the fluid held within the syringe 200 into the patient's vasculature, a caregiver or automated machine will typically depress the plunger 202 of the syringe 200 or other mechanism all the way into the body member 206 until the plunger 202 and the rubber seal 208 bottoms out against the bottom surface 211 of the syringe 200, which can cause the typically resilient rubber seal 208 to be compressed between the generally rigid plunger 202 and the bottom surface 211 of the syringe. When this occurs, the seal 208 on the end of the plunger 202, which is typically made from a rubber or other resilient material, can rebound when the force exerted by a caregiver on the plunger 202 is removed.
The force that the cannula 204 exerts on the end surface 63 of the seal member 60 can be sufficient to cause a substantially fluid-tight seal between the cannula 204 and the seal member 60 end surface 63, so that all or substantially all of the fluid within the syringe 200 is caused to flow into the opening 100 when the syringe 200 is joined with the connector 10 in this compressed seal 60 manner. In some embodiments, the elongate member 118 does not pierce or penetrate the seal 60. For example, in some embodiments, the elongate portion 118 comes into close proximity with (e.g., in contact with, adjacent to, or positioned very near) the interior surface of the top of the seal member when the connector 10 is opened without entering or going through the slit 70 of the seal 60. In some embodiments, the seal member 60 can be configured to have a naturally open position, without requiring the elongate portion 10 to open the seal member 60.
Thus, when the seal member 60 is in the open position, as illustrated in
In the illustrated embodiment of
Medical personnel periodically flush connectors and intravenous tubing with saline, especially after administration of medications and drawing of blood. The saline flush serves to ensure that the full dose of medication is given to the patient and that there is also no residual blood left in the tubing or connector. Residual blood in the connector may clot and/or become a source of bacterial contamination. Because a connector is used to introduce fluids intravenously, contamination can be introduced to the patient rapidly causing systemic infection. Thus further advantages of a transparent connector 10 include enabling medical personnel to detect subtle changes in the appearance of the saline left in the intravenous line such as blood clots, as well as turbidity or cloudiness which may be an indication of connector contamination. A connector leak may go undetected if the leak is in a non-transparent region of the connector 10. Embodiments of the connector 10 described herein have the added advantage of exposing all connector components to visual inspection, thus assuring medical personnel that the connector 10 is functioning correctly at all times. The transparent connector 10 also allows medical personnel to readily assess the efficacy of the flush because residual fluid that remains in the connector can be clearly visible. In some embodiments, the body 20 material can include components that magnify the flow path region, which makes the flow path visual appearance larger and readily visible.
In the event that even sealing engagement is not made between the syringe 200 and the seal 60, fluid may spread into the body cavity 42, or between the seal 60 and the inner portion 118, rather than flowing directly from the syringe into the elongate portion 118 radial openings 100. Medical personnel administering the medicament can immediately observe the leaking fluid and address the leak by, for example, stopping the medicament administration, and/or by cleaning, flushing or removing and replacing the connector 10 after the medicament is administered. The ability to monitor the fluid levels and location provides a real-time assessment of the effectiveness and non-leak success of the fluid transfer. Knowledge of whether any of the transfer fluid either remains in the fluid conduit or has escaped from the primary internal fluid conduit allows timely flushing and/or replacement of a connector that is contaminated, or at high risk of contamination due to undesirable residual fluids. The ability to quickly respond to fluid in the generally non-fluid flow cavities reduces the potential risks to the patient due to fouled lines, conduits, medical connectors, or other medical implements.
In this position, when the plunger 202 has been completely depressed relative to the syringe 200 such that no additional fluid is being forced from the syringe 200, the fluid flow within the syringe 200 and, hence, the connector 10, stops.
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiments of
With reference to
As similarly described above, the body member 220 can include a proximal end 222, a distal end 224, external threads 226, a proximal opening 228, and a distal opening 330. The body 220 can further include a neck 232, a shoulder 236, an annular channel 238, an internal surface 244, an outer surface 246, and a distal flange 252. These body 220 features include similar characteristics to the features described herein with respect to body 20. The seal member 260 correspondingly has characteristics similar to seal 60 described herein, such as a proximal end 262, flange face 263, lip 266, slit 270, prongs 272, flange 274, convolutes 280, distal opening 282, and middle portion 284.
As similarly described above, the body member 220 and the base member 290 can be joined together to provide a rigid housing that substantially encapsulates the seal member 260, the support member 294, and the regulator 350. The body member 220 and the base member 290 can be joined together using any suitable method or features, including but not limited to the methods or features described elsewhere herein for joining the body member 20 with the base member 90. The body 220, the seal 260, the support 294, the elongate portion 318, and the base 290 can be comprised of transparent material that provides a substantially clear view through the walls of each component of the connector 210. The tip portion 292 can be transparent through the outer surface 304 and the inner surface 306 such that an internal fluid disposed within the tip portion is visible. The transparent characteristics of the body 220, the seal 260, and elongate portion 318 provide a direct and substantially clear optical visual, or view, of the medicament fluid flow from a medical implement through the connector 210. Medical personnel can observe a medicament administered to a patient with optical clarity and readily determine issues or risks encountered due to fluid leakage past seal 260, backflow into the connector 210, blocked flow, or contamination in the connector.
As illustrated in
The regulator 350 can include the valve 358 that is defined by the slit 360 disposed on the dome shaped, or arcuate, geometry of the regulator distal end. The valve 358 regulates fluid flow through the connector 210 male tip protrusion 316 and the radial opening 300. The slits 360 can include one or a plurality of apertures through the regulator 350 distal end, and can be in any general arrangement, e.g. crossed, triangular, centered, offset, or the like. The slits 360 can be biased toward one another in a closed configuration that prevents fluid flow through the connector. The slits 360 can be configured to open and allow flow only after a predetermined selective pressure differential threshold is attained between the regulator body 352 interior volume and the distal pressure in the connector base 290 or the conduit 212. The slits 360 have a higher resistance to deflection induced by pressure differentials across the regulator distal wall thickness than the thin walled portion of the regulator body 352.
The regulator 350 can compensate for negative flow effects, e.g. during syringe removal from the connector, or syringe seal springback. The thin walls of the regulator body 352 can deflect radially inward when the proximally directed vacuum pressure effect occurs. The slits 360 can be configured to not deflect or only minimally deflect under the same pressure effect. In this way, the thin walls of body 352 deflect and compensate and absorb the pressure differential while the fluid downstream of, or distal to, the regulator slits 360 experiences little or none of the pressure effects that can draw fluid into the connector 210 or from the patient into the conduit 212. The slits 360 can deflect when a sufficient pressure differential exists and proximally directed fluid flow is intended, such as when blood is drawn from the patient. The slits 360 can also be configured to provide a greater resistance to proximally directed flow, and a lesser resistance to distally directed flow. The lesser distal flow resistance provides ease of delivery of medicament from a syringe through the connector 210 to the patient.
The regulator 350 or any other embodiment of a regulator, valve, or valve member disclosed herein and any of the components or features thereof can be constructed from a number of different materials, including silicone-based deformable materials, rubbers, or other suitable materials. Silicone-based deformable materials are among those that form fluid-tight closures with plastics and other rigid polymeric or metallic materials. In some embodiments, the regulator 350 can be flexible, elastomeric, and/or resilient. In some embodiments, the regulator 350 can be made from the same material as the seal member 260.
The support 294 includes some features that are similar to base 90 described above. These features include an elongate portion 318, a tip portion 292, a tip 310, a radial opening 300, and an annulus 308. The support 294 differs in that the support is not integrally formed with the base 290, and includes a distal portion 340 configured to engage the second valve, or regulator 350.
The support 294 distal portion 340 can extend distally from a seal support wall 320. The distal portion 340 can include a hollow interior that forms a part of the conduit 302 of the elongate portion 318, and extends to a distal opening 349. The distal portion 340 can include two axially spaced radially outward directed annular protrusions 344, 346, and at least one opening 342 generally positioned between the wall 320 and the protrusion 344. In the illustrated embodiment of
The support 294 distal portion 340 is configured to be received in the interior volume of the regulator 350 through the regulator opening 356. A volume 343 is defined between the outer surface of the distal portion 340 and the inner surface of the regulator 350. The volume 343 provides the space for the regulator body 352 thin walls to deflect radially inward when a pressure differential inducing event occurs. Additional details of the negative pressure compensation support 294 and regulator 350 are disclosed in U.S. patent application Ser. No. 12/730,074, which is hereby incorporated by reference in its entirety.
In some embodiments, a diverter 341, or ball, can be disposed within or adjacent the conduit 302 flow path. The diverter 341 is positioned in the flow path and redirects the moving fluid into and toward the volume 343 to preclude stagnant fluid in the volume 343. Thus, the fluid goes around the diverter 341, entering the volume 343 at a first axial position of the diverter 341 and then re-entering the flow path conduit 302 at a second axial position of the diverter 341. In some embodiments, the diverter 341 can have a variety of diameters, e.g. smaller than, the same as, or greater than the inner diameter of the flow path 302. As shown, the diverter 341 is greater in diameter than the flow path 302 and thus is frictionally retained within the openings 342 and conduit 302 inner diameter walls. The diverter 341 can be formed from a generally rigid material such as nylon, or a semi-rigid or flexible material, or any other suitable material, e.g. the same material as the support member 294, or the like. In some embodiments, the flow diverter can have any geometric shape, e.g. rounded, smooth, curved, oval, square, rectangular, triangular, or polygonal, or the like. In some embodiments, the conduit 302 can include a groove or other geometric shape to receive the diverter 341.
In some embodiments, the fluid diverter can interrupt the substantially linear or laminar flow path of fluid between the proximal and distal ends that can otherwise occur inside of the support member 294 and can increase the lateral fluid flow through the volume 343, thereby preventing or diminishing fluid stagnation in the volume 343. In some embodiments, the increased fluid flow through the volume 343 can prevent or diminish the risk of clotting (in the event that blood is transported through the connector 210), bacteria development, or other adverse affects that can result from stagnant fluid inside the connector 210.
The base 290 includes some features that are similar to base 90 described above. These features include protrusions 312, a shroud 298, internal threads 328, a male tip protrusion 316, a distal end 324, a distal face 326, and an opening 314. The base 290 differs in that the base is not integrally formed with the support 294, and includes a cavity 331 defined by inside surface 330 of wall 332 and configured to encompass the second valve, or regulator 350. The base 290 can include one or more openings 334 that can be formed through a portion of the base member 290 to provide an airway between the ambient atmosphere and the outside surface of the body portion 352 of the regulator 350. The base 290 can further include a circumferential slot or groove 329 extending around or substantially around the outer surface of the base member 290 to provide an area of traction to be grasped by an operator. Such a groove also permits a more uniform wall thickness in the area of the base member 290 to enhance the efficiency of manufacture and the transparent characteristics of the connector 210.
With reference to
With reference to
Although some specific examples have been provided herein, it should be understood that a transparent connector and/or backflow resistance module can be incorporated into many other types of medical implements and/or connectors than those specifically disclosed herein. For example, a backflow resistance module can be incorporated into a y-site connector, or into a connector providing access to an IV bag or other medication container, or into a catheter line.
Any features of the embodiments shown and/or described in the figures that have not been expressly described in this text, such as distances, proportions of components, etc. are also intended to form part of this disclosure. Additionally, although these inventions have been disclosed in the context of various embodiments, features, aspects, and examples, it will be understood by those skilled in the art that embodiments of the present invention extend beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with, or substituted for, one another in order to perform varying modes of the disclosed inventions. Thus, it is intended that the scope of the present invention disclosed herein should not be limited by the particular disclosed embodiments described herein.
The present application is a continuation of U.S. patent application Ser. No. 14/961,163, filed Dec. 7, 2015, pending, which is a continuation of U.S. patent application Ser. No. 14/520,240, filed Oct. 21, 2014, (now U.S. Pat. No. 9,205,243, issued Dec. 8, 2015), which is a continuation of U.S. patent application Ser. No. 14/309,489, filed Jun. 19, 2014 (now U.S. Pat. No. 9,192,753, issued Nov. 24, 2015), which is a continuation of U.S. patent application Ser. No. 13/106,781, filed May 12, 2011 (now U.S. Pat. No. 8,758,306, issued Jun. 24, 2014), which claims the benefit of U.S. Provisional Patent Application No. 61/345,554, filed May 17, 2010 (entitled “MEDICAL CONNECTOR WITH VISIBLE INTERNAL FLUID PATHWAY”) and U.S. Provisional Patent Application No. 61/392,426, filed Oct. 12, 2010 (entitled “MEDICAL CONNECTORS AND METHODS OF USE”), the entire disclosures of which are hereby incorporated by reference. This application also hereby incorporates by reference the entire disclosures of U.S. patent application Ser. No. 12/730,074 entitled “MEDICAL CONNECTORS AND METHODS OF USE”, filed on Mar. 23, 2010 (now U.S. Pat. No. 8,454,579, issued Jun. 4, 2013), U.S. patent application Ser. No. 11/924,494 entitled “MEDICAL CONNECTOR”, filed on Oct. 25, 2007 (now U.S. Pat. No. 8,105,314, issued Jan. 31, 2012), and U.S. patent application Ser. No. 11/381,526 entitled “MEDICAL VALVE AND METHOD OF USE”, filed on May 3, 2006 (now U.S. Pat. No. 7,717,884, issued May 18, 2010).
Number | Name | Date | Kind |
---|---|---|---|
274447 | Kennish | Mar 1883 | A |
1578517 | Hein | Mar 1926 | A |
1923501 | Perry | Aug 1933 | A |
2210098 | Ravenscroft | Aug 1940 | A |
2289677 | Perelson | Jul 1942 | A |
2347988 | Burke | Oct 1943 | A |
2577780 | Lockhart | Dec 1951 | A |
2688979 | Kendrick | Sep 1954 | A |
2756282 | Deane | Jul 1956 | A |
2756740 | Deane | Jul 1956 | A |
2809665 | Crowe | Oct 1957 | A |
2847995 | Adams | Aug 1958 | A |
2999499 | Willet | Sep 1961 | A |
3134380 | Armao | May 1964 | A |
3135261 | Carroll | Jun 1964 | A |
3171412 | Braun | Mar 1965 | A |
3176021 | Volungis et al. | Mar 1965 | A |
3191655 | McCord | Jun 1965 | A |
3193154 | Bross et al. | Jul 1965 | A |
3334860 | Bolton, Jr. | Aug 1967 | A |
3352531 | Kilmarx | Nov 1967 | A |
3354881 | Bloch | Nov 1967 | A |
3385301 | Harautuneian | May 1968 | A |
3502097 | Muller | Mar 1970 | A |
3534771 | Eyerdam et al. | Oct 1970 | A |
3570484 | Steer et al. | Mar 1971 | A |
3630199 | Gangarosa | Dec 1971 | A |
3648684 | Barnwell et al. | Mar 1972 | A |
3659602 | Cloyd | May 1972 | A |
3717174 | Dewall | Feb 1973 | A |
3726282 | Patel | Apr 1973 | A |
3788519 | Mengel | Jan 1974 | A |
3830241 | Dye et al. | Aug 1974 | A |
3831629 | Mackal et al. | Aug 1974 | A |
3852385 | Huggins | Dec 1974 | A |
3861388 | Vaughn | Jan 1975 | A |
3889675 | Stewart | Jun 1975 | A |
3896853 | Bernhard | Jul 1975 | A |
3965910 | Fisher | Jun 1976 | A |
3974832 | Kruck | Aug 1976 | A |
3976063 | Henneman et al. | Aug 1976 | A |
3976073 | Quick et al. | Aug 1976 | A |
3977403 | Patel | Aug 1976 | A |
3986508 | Barrington | Oct 1976 | A |
3993063 | Larrabee | Nov 1976 | A |
3994293 | Ferro | Nov 1976 | A |
4005710 | Zeddies et al. | Feb 1977 | A |
4019512 | Tenczar | Apr 1977 | A |
4022205 | Tenczar | May 1977 | A |
4040420 | Speer | Aug 1977 | A |
4076285 | Martinez | Feb 1978 | A |
4079738 | Dunn et al. | Mar 1978 | A |
4080965 | Phillips | Mar 1978 | A |
4121585 | Becker, Jr. | Oct 1978 | A |
4128098 | Bloom et al. | Dec 1978 | A |
4133441 | Mittleman et al. | Jan 1979 | A |
4143853 | Abramson | Mar 1979 | A |
4149535 | Volder | Apr 1979 | A |
4161949 | Thanawalla | Jul 1979 | A |
4186775 | Muroi | Feb 1980 | A |
4187846 | Lolachi et al. | Feb 1980 | A |
4191183 | Mendelson | Mar 1980 | A |
4198983 | Becker et al. | Apr 1980 | A |
4200096 | Charvin | Apr 1980 | A |
4214779 | Losell | Jul 1980 | A |
4219912 | Adams | Sep 1980 | A |
4243034 | Brandt | Jan 1981 | A |
4257416 | Prager | Mar 1981 | A |
D259278 | McCaw et al. | May 1981 | S |
4294249 | Sheehan et al. | Oct 1981 | A |
4294250 | Dennehey | Oct 1981 | A |
4296949 | Muetterties et al. | Oct 1981 | A |
4306705 | Svensson | Dec 1981 | A |
4324239 | Gordon et al. | Apr 1982 | A |
4328802 | Curley et al. | May 1982 | A |
4329987 | Rogers et al. | May 1982 | A |
4334551 | Pfister | Jun 1982 | A |
4338933 | Bayard et al. | Jul 1982 | A |
4342315 | Jackson | Aug 1982 | A |
4346703 | Dennehey et al. | Aug 1982 | A |
4362156 | Feller et al. | Dec 1982 | A |
4387879 | Tauschinski | Jun 1983 | A |
RE31315 | Jenkins et al. | Jul 1983 | E |
4392851 | Elias | Jul 1983 | A |
4405163 | Voges et al. | Sep 1983 | A |
4405312 | Gross et al. | Sep 1983 | A |
4411662 | Pearson | Oct 1983 | A |
4417890 | Dennehey et al. | Nov 1983 | A |
4421296 | Stephens | Dec 1983 | A |
4429856 | Jackson | Feb 1984 | A |
4432759 | Gross et al. | Feb 1984 | A |
4432765 | Oscarsson | Feb 1984 | A |
4434810 | Atkinson | Mar 1984 | A |
4439188 | Dennehey et al. | Mar 1984 | A |
4439193 | Larkin | Mar 1984 | A |
4449693 | Gerea | May 1984 | A |
4457749 | Bellotti et al. | Jul 1984 | A |
4483368 | Panthafer | Nov 1984 | A |
4508367 | Oreopoulos et al. | Apr 1985 | A |
4511359 | Vaillancourt | Apr 1985 | A |
4512766 | Vaillancourt | Apr 1985 | A |
4535818 | Duncan et al. | Aug 1985 | A |
4564054 | Gustaysson | Jan 1986 | A |
4592356 | Guiterrez | Jun 1986 | A |
4607868 | Harvey et al. | Aug 1986 | A |
4610469 | Wolff-Mooij | Sep 1986 | A |
4617012 | Vaillancourt | Oct 1986 | A |
4619640 | Poholshy et al. | Oct 1986 | A |
4621654 | Holter | Nov 1986 | A |
4623068 | Brown et al. | Nov 1986 | A |
4645494 | Lee et al. | Feb 1987 | A |
4666429 | Stone | May 1987 | A |
4673400 | Martin | Jun 1987 | A |
4676228 | Krasner et al. | Jun 1987 | A |
4683916 | Raines | Aug 1987 | A |
4706487 | Bandou et al. | Nov 1987 | A |
4710168 | Schwab et al. | Dec 1987 | A |
4725267 | Vaillancourt | Feb 1988 | A |
4730635 | Linden | Mar 1988 | A |
4752292 | Lopez et al. | Jun 1988 | A |
D296592 | Wellenstam | Jul 1988 | S |
4758224 | Siposs | Jul 1988 | A |
4759756 | Forman et al. | Jul 1988 | A |
4775369 | Schwartz | Oct 1988 | A |
4778447 | Velde et al. | Oct 1988 | A |
4778453 | Lopez | Oct 1988 | A |
4781702 | Herrli | Nov 1988 | A |
4804015 | Albinsson | Feb 1989 | A |
D300177 | Bellotti et al. | Mar 1989 | S |
4810241 | Rogers et al. | Mar 1989 | A |
4813938 | Raulerson | Mar 1989 | A |
4819684 | Zaugg et al. | Apr 1989 | A |
4832214 | Schrader et al. | May 1989 | A |
4834664 | Lin | May 1989 | A |
4834716 | Ogle, II | May 1989 | A |
D303013 | Konopka | Aug 1989 | S |
4874377 | Newgard et al. | Oct 1989 | A |
4878897 | Katzin | Nov 1989 | A |
4880414 | Whipple | Nov 1989 | A |
4883456 | Holter | Nov 1989 | A |
4889527 | Herrli | Dec 1989 | A |
4915687 | Sivert | Apr 1990 | A |
4917668 | Haindl | Apr 1990 | A |
4919167 | Manska | Apr 1990 | A |
4928212 | Benavides | May 1990 | A |
4934657 | Dodson | Jun 1990 | A |
4943896 | Johnson | Jul 1990 | A |
4946445 | Lynn | Aug 1990 | A |
4963133 | Whipple | Oct 1990 | A |
4964855 | Todd et al. | Oct 1990 | A |
4966199 | Ruschke | Oct 1990 | A |
4969883 | Gilbert et al. | Nov 1990 | A |
D314050 | Sone | Jan 1991 | S |
4985399 | Matsuda et al. | Jan 1991 | A |
4987181 | Bichon et al. | Jan 1991 | A |
4991413 | Arnalda | Feb 1991 | A |
4991629 | Ernesto et al. | Feb 1991 | A |
4991745 | Brown | Feb 1991 | A |
4995863 | Nichols et al. | Feb 1991 | A |
4998713 | Vaillancourt | Mar 1991 | A |
4998927 | Vaillancourt | Mar 1991 | A |
5006114 | Rogers et al. | Apr 1991 | A |
5009490 | Kuono et al. | Apr 1991 | A |
5018532 | Ethridge, III | May 1991 | A |
5024657 | Needham et al. | Jun 1991 | A |
5030210 | Alchas | Jul 1991 | A |
5031675 | Lindqren | Jul 1991 | A |
5041087 | Loo et al. | Aug 1991 | A |
5046456 | Heyman et al. | Sep 1991 | A |
5049128 | Duquette | Sep 1991 | A |
D321250 | Jepson et al. | Oct 1991 | S |
D321251 | Jepson et al. | Oct 1991 | S |
5061253 | Yoshida | Oct 1991 | A |
5064416 | Newgard | Nov 1991 | A |
5065783 | Ogle, II | Nov 1991 | A |
5071411 | Hillstead | Dec 1991 | A |
5098385 | Walsh | Mar 1992 | A |
5098405 | Peterson et al. | Mar 1992 | A |
5098406 | Sawyer | Mar 1992 | A |
5100394 | Dudar et al. | Mar 1992 | A |
5108380 | Heritze et al. | Apr 1992 | A |
5114408 | Fleischhaker et al. | May 1992 | A |
5116361 | Kim et al. | May 1992 | A |
5122123 | Vaillancourt | Jun 1992 | A |
5125915 | Berry et al. | Jun 1992 | A |
5135489 | Jepson et al. | Aug 1992 | A |
5137524 | Lynn et al. | Aug 1992 | A |
5147333 | Raines | Sep 1992 | A |
5154703 | Bonaldo | Oct 1992 | A |
5156600 | Young | Oct 1992 | A |
5158554 | Jepson et al. | Oct 1992 | A |
5163922 | McElveen, Jr. et al. | Nov 1992 | A |
5167238 | Newman | Dec 1992 | A |
5167636 | Clement | Dec 1992 | A |
5171234 | Jepson et al. | Dec 1992 | A |
5180761 | Shiao | Jan 1993 | A |
5188620 | Jepson et al. | Feb 1993 | A |
5190067 | Paradis et al. | Mar 1993 | A |
5199947 | Lopez et al. | Apr 1993 | A |
5201717 | Wyatt et al. | Apr 1993 | A |
5201722 | Moorehead et al. | Apr 1993 | A |
5203775 | Frank et al. | Apr 1993 | A |
5211638 | Dudar et al. | May 1993 | A |
5215538 | Larkin | Jun 1993 | A |
5221271 | Nicholson et al. | Jun 1993 | A |
5224515 | Foster et al. | Jul 1993 | A |
5242393 | Brimhall et al. | Sep 1993 | A |
5242423 | Goodsir et al. | Sep 1993 | A |
5242425 | Whine et al. | Sep 1993 | A |
5242432 | DeFrank | Sep 1993 | A |
5249598 | Schmidt | Oct 1993 | A |
5251873 | Atkinson et al. | Oct 1993 | A |
5253842 | Huebscher et al. | Oct 1993 | A |
5255676 | Russo | Oct 1993 | A |
5256155 | Yerlikaya et al. | Oct 1993 | A |
5267966 | Paul | Dec 1993 | A |
5269771 | Thomas et al. | Dec 1993 | A |
5273533 | Bonaldo | Dec 1993 | A |
5280876 | Atkins | Jan 1994 | A |
5284475 | Mackal | Feb 1994 | A |
5290254 | Vaillancourt | Mar 1994 | A |
5292308 | Ryan | Mar 1994 | A |
5293902 | Lapierie | Mar 1994 | A |
5295657 | Atkinson | Mar 1994 | A |
5295658 | Atkinson et al. | Mar 1994 | A |
5301686 | Newman | Apr 1994 | A |
5306265 | Ragazzi | Apr 1994 | A |
5312083 | Ekman | May 1994 | A |
5312377 | Dalhon | May 1994 | A |
5322518 | Schneider | Jun 1994 | A |
5324270 | Kayon et al. | Jun 1994 | A |
5336192 | Palestrant | Aug 1994 | A |
5342316 | Wallace | Aug 1994 | A |
5342326 | Peppel et al. | Aug 1994 | A |
5344414 | Lopez et al. | Sep 1994 | A |
5348542 | Ellis | Sep 1994 | A |
5353837 | Faust | Oct 1994 | A |
5356396 | Wyatt et al. | Oct 1994 | A |
5360413 | Leason et al. | Nov 1994 | A |
5380306 | Brinon | Jan 1995 | A |
5389086 | Attermeier et al. | Feb 1995 | A |
5398530 | Derman | Mar 1995 | A |
5401245 | Haining | Mar 1995 | A |
5402826 | Molnar et al. | Apr 1995 | A |
5402982 | Atkinson et al. | Apr 1995 | A |
5407437 | Heimreid | Apr 1995 | A |
5409471 | Atkinson et al. | Apr 1995 | A |
5395348 | Ryan | May 1995 | A |
5411483 | Loomas et al. | May 1995 | A |
5411499 | Dudar et al. | May 1995 | A |
5417673 | Gordon | May 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5439452 | McCarty | Aug 1995 | A |
5441487 | Vedder | Aug 1995 | A |
5442941 | Kahonen et al. | Aug 1995 | A |
5456676 | Nelson et al. | Oct 1995 | A |
5462255 | Rosen et al. | Oct 1995 | A |
5470319 | Mayer | Nov 1995 | A |
5474544 | Lynn | Dec 1995 | A |
5480393 | Bommarito | Jan 1996 | A |
5487731 | Denton | Jan 1996 | A |
5501426 | Atkinson | Mar 1996 | A |
5501526 | Asai et al. | Mar 1996 | A |
5509433 | Paradis | Apr 1996 | A |
5514116 | Vaillancourt et al. | May 1996 | A |
5520665 | Fleetwood | May 1996 | A |
5522804 | Lynn | Jun 1996 | A |
5533708 | Atkinson et al. | Jul 1996 | A |
5533996 | Murphey et al. | Jul 1996 | A |
5535771 | Purdy et al. | Jul 1996 | A |
5535785 | Werge et al. | Jul 1996 | A |
5540661 | Tomisaka et al. | Jul 1996 | A |
5549566 | Elias et al. | Aug 1996 | A |
5549577 | Siegel et al. | Aug 1996 | A |
5549651 | Lynn | Aug 1996 | A |
5554136 | Luther | Sep 1996 | A |
5555908 | Edwards et al. | Sep 1996 | A |
5556388 | Johlin, Jr. | Sep 1996 | A |
5562632 | Davila et al. | Oct 1996 | A |
5569235 | Ross et al. | Oct 1996 | A |
5573516 | Tyner | Nov 1996 | A |
5577706 | King | Nov 1996 | A |
5578059 | Patzer | Nov 1996 | A |
5597536 | Mayer | Jan 1997 | A |
5603706 | Wyatt et al. | Feb 1997 | A |
5609584 | Gettig et al. | Mar 1997 | A |
5616129 | Mayer | Apr 1997 | A |
5616130 | Mayer | Apr 1997 | A |
5617897 | Myers | Apr 1997 | A |
5620424 | Abramson | Apr 1997 | A |
5620434 | Brony | Apr 1997 | A |
5624414 | Boettger | Apr 1997 | A |
5632735 | Wyatt et al. | May 1997 | A |
5639810 | Smith, III et al. | Jun 1997 | A |
5660205 | Epstein | Aug 1997 | A |
5667500 | Palmer et al. | Sep 1997 | A |
5669891 | Vaillancourt | Sep 1997 | A |
5674206 | Allton et al. | Oct 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5690612 | Lopez et al. | Nov 1997 | A |
5690865 | Kindt-Larsen et al. | Nov 1997 | A |
5694686 | Lopez | Dec 1997 | A |
5695466 | Lopez et al. | Dec 1997 | A |
5699821 | Paradis | Dec 1997 | A |
5700248 | Lopez | Dec 1997 | A |
5707357 | Mikhail et al. | Jan 1998 | A |
5728751 | Patnaik | Mar 1998 | A |
5730418 | Feith et al. | Mar 1998 | A |
5738663 | Lopez | Apr 1998 | A |
5749861 | Guala et al. | May 1998 | A |
5769825 | Lynn | Jun 1998 | A |
5775671 | Cote, Sr. | Jul 1998 | A |
5776113 | Daugherty et al. | Jul 1998 | A |
5782816 | Werschmidt et al. | Jul 1998 | A |
5788215 | Ryan | Aug 1998 | A |
5797897 | Jepson et al. | Aug 1998 | A |
5806551 | Meloul et al. | Sep 1998 | A |
5806831 | Paradis | Sep 1998 | A |
5807348 | Zinger et al. | Sep 1998 | A |
5807349 | Person et al. | Sep 1998 | A |
5810789 | Powers et al. | Sep 1998 | A |
5817069 | Arnett | Oct 1998 | A |
5820601 | Mayer | Oct 1998 | A |
5833213 | Ryan | Nov 1998 | A |
5836923 | Mayer | Nov 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5843044 | Moorehead | Dec 1998 | A |
5843046 | Motisi et al. | Dec 1998 | A |
5846233 | Lilley et al. | Dec 1998 | A |
5865807 | Blake, III | Feb 1999 | A |
5873862 | Lopez | Feb 1999 | A |
5882348 | Winterton et al. | Mar 1999 | A |
5899888 | Jepson et al. | May 1999 | A |
5901942 | Lopez | May 1999 | A |
5911710 | Barry et al. | Jun 1999 | A |
5928204 | Lopez | Jul 1999 | A |
5935620 | Baudin | Aug 1999 | A |
5947954 | Bonaldo | Sep 1999 | A |
5954313 | Ryan | Sep 1999 | A |
5957898 | Jepson et al. | Sep 1999 | A |
5967490 | Pike | Oct 1999 | A |
5979868 | Wu et al. | Nov 1999 | A |
5984903 | Nadal | Nov 1999 | A |
6009902 | Troiani et al. | Jan 2000 | A |
6019748 | Lopez | Feb 2000 | A |
6029946 | Doyle | Feb 2000 | A |
6036171 | Weinheimer et al. | Mar 2000 | A |
6039302 | Cote, Sr. et al. | Mar 2000 | A |
6048335 | Mayer | Apr 2000 | A |
6050978 | Orr et al. | Apr 2000 | A |
6063062 | Paradis | May 2000 | A |
6079432 | Paradis | Jun 2000 | A |
6089541 | Weinheier et al. | Jul 2000 | A |
6113068 | Ryan | Sep 2000 | A |
6116571 | Hettinger | Sep 2000 | A |
6117114 | Paradis | Sep 2000 | A |
6132403 | Lopez | Oct 2000 | A |
6132404 | Lopez | Oct 2000 | A |
6142446 | Leinsing | Nov 2000 | A |
6152900 | Mayer | Nov 2000 | A |
6162206 | Bindokas et al. | Dec 2000 | A |
6162251 | Kredovski | Dec 2000 | A |
6168137 | Paradis | Jan 2001 | B1 |
6170800 | Meloul et al. | Jan 2001 | B1 |
6171287 | Lynn | Jan 2001 | B1 |
6177037 | Mayer | Jan 2001 | B1 |
6183448 | Mayer | Feb 2001 | B1 |
6189859 | Rohrbough et al. | Feb 2001 | B1 |
6206861 | Mayer | Mar 2001 | B1 |
6210624 | Mayer | Apr 2001 | B1 |
6213996 | Jepson et al. | Apr 2001 | B1 |
6228065 | Lynn | May 2001 | B1 |
6228069 | Barth et al. | May 2001 | B1 |
6245048 | Fangrow et al. | Jun 2001 | B1 |
6254579 | Cogger et al. | Jul 2001 | B1 |
6261282 | Jepson et al. | Jul 2001 | B1 |
6261630 | Nazarova et al. | Jul 2001 | B1 |
6279783 | Brown et al. | Aug 2001 | B1 |
6290206 | Doyle | Sep 2001 | B1 |
6299131 | Ryan | Oct 2001 | B1 |
6299132 | Wienheimer | Oct 2001 | B1 |
6325782 | Lopez | Dec 2001 | B1 |
6364869 | Bonaldo | Apr 2002 | B1 |
6428520 | Lopez et al. | Aug 2002 | B1 |
6444324 | Yang et al. | Sep 2002 | B1 |
6482188 | Rogers et al. | Nov 2002 | B1 |
D468016 | Mosler et al. | Dec 2002 | S |
6530504 | Socier | Mar 2003 | B2 |
6541802 | Doyle | Apr 2003 | B2 |
6543745 | Enerson | Apr 2003 | B1 |
6572592 | Lopez | Jun 2003 | B1 |
6585229 | Cote, Sr. et al. | Jul 2003 | B2 |
6595964 | Finley et al. | Jul 2003 | B2 |
6595981 | Huet | Jul 2003 | B2 |
6599273 | Lopez | Jul 2003 | B1 |
6605076 | Jepson et al. | Aug 2003 | B1 |
6609696 | Enerson | Aug 2003 | B2 |
6635044 | Lopez | Oct 2003 | B2 |
6651956 | Miller | Nov 2003 | B2 |
6656517 | Michal et al. | Dec 2003 | B2 |
6669673 | Lopez | Dec 2003 | B2 |
6669681 | Jepson et al. | Dec 2003 | B2 |
6673053 | Wang et al. | Jan 2004 | B2 |
6682509 | Lopez | Jan 2004 | B2 |
6689109 | Lynn | Feb 2004 | B2 |
6695817 | Fangrow, Jr. | Feb 2004 | B1 |
6706022 | Leinsing et al. | Mar 2004 | B1 |
6712791 | Lui et al. | Mar 2004 | B2 |
6727294 | Kanayama et al. | Apr 2004 | B2 |
6740063 | Lynn | May 2004 | B2 |
6745998 | Doyle | Jun 2004 | B2 |
6755391 | Newton et al. | Jun 2004 | B2 |
6758833 | Lopez | Jul 2004 | B2 |
6783709 | Harreld et al. | Aug 2004 | B2 |
6802490 | Leinsing | Oct 2004 | B2 |
6808161 | Hishikawa | Oct 2004 | B1 |
6832994 | Niedospial, Jr. et al. | Dec 2004 | B2 |
6840501 | Doyle | Jan 2005 | B2 |
6848139 | Simon et al. | Feb 2005 | B2 |
6866656 | Tingey et al. | Mar 2005 | B2 |
6869426 | Ganem | Mar 2005 | B2 |
6871838 | Raines et al. | Mar 2005 | B2 |
6883778 | Newton et al. | Apr 2005 | B1 |
6892998 | Newton | May 2005 | B2 |
6908459 | Harding et al. | Jun 2005 | B2 |
6916309 | Fangrow, Jr. | Jul 2005 | B2 |
6932795 | Lopez et al. | Aug 2005 | B2 |
6964406 | Doyle | Nov 2005 | B2 |
6991215 | Kiehne | Jan 2006 | B2 |
6994315 | Ryan et al. | Feb 2006 | B2 |
6997917 | Niedospial, Jr. et al. | Feb 2006 | B2 |
7014169 | Newton et al. | Mar 2006 | B2 |
7025744 | Utterberg et al. | Apr 2006 | B2 |
7033339 | Lynn | Apr 2006 | B1 |
7037302 | Vaillancourt | May 2006 | B2 |
7044441 | Doyle | May 2006 | B2 |
7074216 | Fowles et al. | Jul 2006 | B2 |
7100890 | Cote et al. | Sep 2006 | B2 |
7104520 | Leinsing et al. | Sep 2006 | B2 |
7114701 | Peppel | Oct 2006 | B2 |
7125396 | Leinsing et al. | Oct 2006 | B2 |
7140592 | Phillips et al. | Nov 2006 | B2 |
7184825 | Leinsing et al. | Feb 2007 | B2 |
D547862 | Dikeman et al. | Jul 2007 | S |
7244249 | Leinsing et al. | Jul 2007 | B2 |
7252652 | Moorehead et al. | Aug 2007 | B2 |
7264859 | Souns et al. | Sep 2007 | B2 |
7306197 | Parrino et al. | Dec 2007 | B2 |
7306199 | Leinsing et al. | Dec 2007 | B2 |
7314061 | Peppel | Jan 2008 | B2 |
7329249 | Bonaldo | Feb 2008 | B2 |
7335182 | Hilaire | Feb 2008 | B1 |
D567941 | Dikeman et al. | Apr 2008 | S |
7357792 | Newton et al. | Apr 2008 | B2 |
D568466 | Dikeman et al. | May 2008 | S |
D569506 | Dikeman et al. | May 2008 | S |
7396348 | Newton et al. | Jul 2008 | B2 |
7422369 | Bergman et al. | Sep 2008 | B2 |
7470261 | Lynn | Dec 2008 | B2 |
7470262 | Hiejima et al. | Dec 2008 | B2 |
7497848 | Leinsing et al. | Mar 2009 | B2 |
7497849 | Fangrow, Jr. | Mar 2009 | B2 |
7510545 | Peppel | Mar 2009 | B2 |
7520489 | Rushke | Apr 2009 | B2 |
7530546 | Ryan et al. | May 2009 | B2 |
7556060 | Guala | Jul 2009 | B2 |
7559530 | Korogi et al. | Jul 2009 | B2 |
7563243 | Mendels | Jul 2009 | B2 |
7581561 | Funamura et al. | Sep 2009 | B2 |
7584767 | Funamura et al. | Sep 2009 | B2 |
7588563 | Guala | Sep 2009 | B2 |
7591449 | Raines et al. | Sep 2009 | B2 |
7600530 | Truitt et al. | Oct 2009 | B2 |
7601141 | Dikeman et al. | Oct 2009 | B2 |
7615035 | Peppel | Nov 2009 | B2 |
7624749 | Guala | Dec 2009 | B2 |
7628774 | Fangrow, Jr. | Dec 2009 | B2 |
7645274 | Whitley | Jan 2010 | B2 |
7651481 | Raybuck | Jan 2010 | B2 |
7666170 | Guala | Feb 2010 | B2 |
7673653 | Mijers et al. | Mar 2010 | B2 |
7691090 | Belley et al. | Apr 2010 | B2 |
7703486 | Costanzo | Apr 2010 | B2 |
7713250 | Harding et al. | May 2010 | B2 |
7717882 | Harding | May 2010 | B2 |
7717886 | Lopez | May 2010 | B2 |
7743799 | Mosler et al. | Jun 2010 | B2 |
7753338 | Desecki | Jul 2010 | B2 |
7753892 | Newton et al. | Jul 2010 | B2 |
7758566 | Simpson et al. | Jul 2010 | B2 |
7763013 | Baldwin et al. | Jul 2010 | B2 |
7763199 | Fangrow | Jul 2010 | B2 |
7771383 | Truitt et al. | Aug 2010 | B2 |
7784766 | Guala | Aug 2010 | B2 |
7799009 | Niedospial, Jr. et al. | Sep 2010 | B2 |
7806873 | Dikeman et al. | Oct 2010 | B2 |
7815168 | Vangsness et al. | Oct 2010 | B2 |
7824393 | Fangrow, Jr. | Nov 2010 | B2 |
7837658 | Cote, Sr. et al. | Nov 2010 | B2 |
7841581 | Thorne, Jr. et al. | Nov 2010 | B2 |
7842026 | Cahill et al. | Nov 2010 | B2 |
7857284 | Kimball et al. | Dec 2010 | B2 |
7857285 | Lee et al. | Dec 2010 | B2 |
7857802 | Brandenburger et al. | Dec 2010 | B2 |
7857805 | Raines | Dec 2010 | B2 |
7862537 | Zinger et al. | Jan 2011 | B2 |
7867204 | Bartholomew et al. | Jan 2011 | B2 |
7879012 | Kane et al. | Feb 2011 | B2 |
7879013 | Smith et al. | Feb 2011 | B2 |
7900659 | Whitley et al. | Mar 2011 | B2 |
7905873 | Rondeau et al. | Mar 2011 | B2 |
7909056 | Truitt et al. | Mar 2011 | B2 |
7914502 | Newton et al. | Mar 2011 | B2 |
7947032 | Harding et al. | May 2011 | B2 |
7954515 | Gerst | Jun 2011 | B2 |
7959614 | Dikeman et al. | Jun 2011 | B2 |
7967797 | Winsor et al. | Jun 2011 | B2 |
7975722 | Kiehne | Jul 2011 | B2 |
7981090 | Plishka et al. | Jul 2011 | B2 |
7981381 | Lurvey et al. | Jul 2011 | B2 |
7984730 | Ziv et al. | Jul 2011 | B2 |
7985206 | Dikeman et al. | Jul 2011 | B2 |
7988128 | Wentling | Aug 2011 | B2 |
7993328 | Whitley | Aug 2011 | B2 |
7998122 | Lynn et al. | Aug 2011 | B2 |
7998134 | Fangrow | Aug 2011 | B2 |
8006953 | Bennett | Aug 2011 | B2 |
D644731 | Fangrow, Jr. | Sep 2011 | S |
8015990 | Pascal et al. | Sep 2011 | B2 |
8021354 | Huang | Sep 2011 | B2 |
8034021 | Mendels | Oct 2011 | B2 |
8034035 | Weaver et al. | Oct 2011 | B2 |
8038663 | Miner | Oct 2011 | B2 |
8042838 | Buckler et al. | Oct 2011 | B2 |
8048038 | Guala | Nov 2011 | B2 |
8052648 | Dikeman et al. | Nov 2011 | B2 |
8057442 | Dikeman et al. | Nov 2011 | B2 |
8062266 | McKinnon et al. | Nov 2011 | B2 |
8062267 | McKinnon et al. | Nov 2011 | B2 |
8062280 | Jepson et al. | Nov 2011 | B2 |
8066648 | Mark | Nov 2011 | B1 |
8066669 | Christensen et al. | Nov 2011 | B2 |
8066670 | Cluff et al. | Nov 2011 | B2 |
8070189 | Yow et al. | Dec 2011 | B2 |
8070725 | Christensen | Dec 2011 | B2 |
8074964 | Mansour et al. | Dec 2011 | B2 |
8092432 | Nordgren | Jan 2012 | B2 |
8096525 | Ryan | Jan 2012 | B2 |
8100868 | Newton et al. | Jan 2012 | B2 |
8100869 | Vangsness et al. | Jan 2012 | B2 |
8105314 | Fangrow | Jan 2012 | B2 |
8122923 | Krause et al. | Feb 2012 | B2 |
8123738 | Vaillancourt | Feb 2012 | B2 |
8133209 | Guala | Mar 2012 | B2 |
8136330 | Ostler et al. | Mar 2012 | B2 |
8137303 | Stout et al. | Mar 2012 | B2 |
8142403 | Carlyon | Mar 2012 | B2 |
8152790 | Lopez et al. | Apr 2012 | B2 |
8156971 | Costanzo | Apr 2012 | B2 |
8157784 | Rogers | Apr 2012 | B2 |
8162006 | Guala | Apr 2012 | B2 |
8162013 | Rosenquist et al. | Apr 2012 | B2 |
8162914 | Kraushaar et al. | Apr 2012 | B2 |
8167863 | Yow | May 2012 | B2 |
8172823 | Rondeau et al. | May 2012 | B2 |
8177760 | Rome et al. | May 2012 | B2 |
8177768 | Leinsing | May 2012 | B2 |
8177772 | Christensen et al. | May 2012 | B2 |
8182452 | Mansourt et al. | May 2012 | B2 |
8197452 | Harding et al. | Jun 2012 | B2 |
8197466 | Yokota et al. | Jun 2012 | B2 |
8211089 | Winsor et al. | Jul 2012 | B2 |
8221363 | Jepson | Jul 2012 | B2 |
8221391 | Fangrow, Jr. | Jul 2012 | B2 |
8235971 | Christensen et al. | Aug 2012 | B2 |
8241268 | Whitley | Aug 2012 | B2 |
8277424 | Pan | Oct 2012 | B2 |
8286657 | Belley et al. | Oct 2012 | B2 |
8287518 | Kitani et al. | Oct 2012 | B2 |
8298195 | Peppel | Oct 2012 | B2 |
8298196 | Mansour | Oct 2012 | B1 |
8328769 | Dikeman et al. | Dec 2012 | B2 |
8337483 | Harding et al. | Dec 2012 | B2 |
8361408 | Lynn | Jan 2013 | B2 |
8366658 | Davis et al. | Feb 2013 | B2 |
8366676 | Harding et al. | Feb 2013 | B2 |
8372043 | Grimm et al. | Feb 2013 | B2 |
8377010 | Harding et al. | Feb 2013 | B2 |
8382741 | Chelak | Feb 2013 | B2 |
8398598 | Carlyon et al. | Mar 2013 | B2 |
8398607 | Fangrow, Jr. | Mar 2013 | B2 |
8403886 | Bialecki et al. | Mar 2013 | B2 |
8403894 | Lynn et al. | Mar 2013 | B2 |
8403905 | Yow | Mar 2013 | B2 |
8408226 | Raines et al. | Apr 2013 | B2 |
8409164 | Fangrow | Apr 2013 | B2 |
8409165 | Niedospial, Jr. et al. | Apr 2013 | B2 |
8414542 | Stroup | Apr 2013 | B2 |
8439880 | Rondeau | May 2013 | B2 |
8444628 | Fangrow, Jr. | May 2013 | B2 |
8454579 | Fangrow, Jr. | Jun 2013 | B2 |
8511352 | Kraus et al. | Aug 2013 | B2 |
8512307 | Fangrow | Aug 2013 | B2 |
8529524 | Newton et al. | Sep 2013 | B2 |
8540692 | Fangrow | Sep 2013 | B2 |
8551037 | Suchecki et al. | Oct 2013 | B2 |
8568371 | Siopes et al. | Oct 2013 | B2 |
8591476 | Winsor et al. | Nov 2013 | B2 |
8628515 | Fangrow, Jr. et al. | Jan 2014 | B2 |
8628516 | Naftalovitz et al. | Jan 2014 | B2 |
8636720 | Truitt et al. | Jan 2014 | B2 |
8640725 | Truitt et al. | Feb 2014 | B2 |
8671964 | Py | Mar 2014 | B2 |
8684994 | Lev et al. | Apr 2014 | B2 |
8702675 | Imai | Apr 2014 | B2 |
8715222 | Truitt et al. | May 2014 | B2 |
8715247 | Mansour et al. | May 2014 | B2 |
8721627 | Albert | May 2014 | B2 |
8757590 | Naftalovitz et al. | Jun 2014 | B2 |
8758306 | Lopez et al. | Jun 2014 | B2 |
8808254 | Lynn | Aug 2014 | B2 |
8814849 | Winsor | Aug 2014 | B1 |
8834432 | Winsor et al. | Sep 2014 | B2 |
8864725 | Ranalletta et al. | Oct 2014 | B2 |
8870846 | Davis et al. | Oct 2014 | B2 |
8870850 | Fangrow, Jr. | Oct 2014 | B2 |
8876784 | Cote, Sr. et al. | Nov 2014 | B2 |
8882742 | Dikeman et al. | Nov 2014 | B2 |
8910919 | Bonnal et al. | Dec 2014 | B2 |
8945084 | Warren et al. | Feb 2015 | B2 |
8951233 | Mansour | Feb 2015 | B2 |
8968261 | Kimball et al. | Mar 2015 | B2 |
8974425 | Tachizaki et al. | Mar 2015 | B2 |
8974433 | Fangrow | Mar 2015 | B2 |
8992501 | Seifert et al. | Mar 2015 | B2 |
9005179 | Fangrow et al. | Apr 2015 | B2 |
9005180 | Seifert et al. | Apr 2015 | B2 |
9017295 | Pan | Apr 2015 | B2 |
9039047 | Imai | May 2015 | B2 |
9044585 | Masuda et al. | Jun 2015 | B2 |
9060921 | Seifert et al. | Jun 2015 | B2 |
9061130 | Truitt et al. | Jun 2015 | B2 |
9067049 | Panian et al. | Jun 2015 | B2 |
9072657 | Seifert et al. | Jul 2015 | B2 |
9107809 | Garfield et al. | Aug 2015 | B2 |
9119950 | Mansour et al. | Sep 2015 | B2 |
9138572 | Zeytoonian et al. | Sep 2015 | B2 |
9186494 | Fangrow et al. | Nov 2015 | B2 |
9192753 | Lopez et al. | Nov 2015 | B2 |
9198831 | Rogers | Dec 2015 | B2 |
9205243 | Lopez et al. | Dec 2015 | B2 |
9205248 | Wu et al. | Dec 2015 | B2 |
9220882 | Belley et al. | Dec 2015 | B2 |
9238129 | Fangrow et al. | Jan 2016 | B2 |
9259565 | Siopes et al. | Feb 2016 | B2 |
9278206 | Fangrow et al. | Mar 2016 | B2 |
9314604 | Bonnal et al. | Apr 2016 | B2 |
9345641 | Kraus et al. | May 2016 | B2 |
9366371 | Naftalovitz et al. | Jun 2016 | B2 |
9370466 | Garfield et al. | Jun 2016 | B2 |
9381339 | Wu et al. | Jul 2016 | B2 |
9393398 | Truitt et al. | Jul 2016 | B2 |
9415200 | Fangrow | Aug 2016 | B2 |
9440060 | Fangrow | Sep 2016 | B2 |
9533137 | Fangrow | Jan 2017 | B2 |
9750926 | Lopez et al. | Sep 2017 | B2 |
20010049508 | Fangrow, Jr. | Dec 2001 | A1 |
20020024036 | Rohrbough et al. | Feb 2002 | A1 |
20020120333 | Keogh et al. | Aug 2002 | A1 |
20020156430 | Haarala et al. | Oct 2002 | A1 |
20030199835 | Leinsing et al. | Oct 2003 | A1 |
20040006330 | Fangrow, Jr. | Jan 2004 | A1 |
20040201216 | Segal et al. | Oct 2004 | A1 |
20050010176 | Dikeman et al. | Jan 2005 | A1 |
20050020981 | Kurth | Jan 2005 | A1 |
20050059952 | Giuliano et al. | Mar 2005 | A1 |
20050121638 | Doyle | Jun 2005 | A1 |
20050124964 | Niedospial, Jr. et al. | Jun 2005 | A1 |
20050212292 | Parrino et al. | Sep 2005 | A1 |
20050222541 | Lopez et al. | Oct 2005 | A1 |
20050234405 | Dikeman et al. | Oct 2005 | A1 |
20050256460 | Rome et al. | Nov 2005 | A1 |
20060004331 | Fangrow, Jr. | Jan 2006 | A1 |
20060161115 | Fangrow, Jr. | Jul 2006 | A1 |
20060200088 | Lopez | Sep 2006 | A1 |
20060200089 | Lopez et al. | Sep 2006 | A1 |
20060200090 | Lopez et al. | Sep 2006 | A1 |
20060206061 | Lopez et al. | Sep 2006 | A1 |
20060211997 | Fangrow, Jr. | Sep 2006 | A1 |
20060211998 | Fangrow, Jr. | Sep 2006 | A1 |
20060211999 | Fangrow, Jr. | Sep 2006 | A1 |
20060212001 | Fangrow, Jr. | Sep 2006 | A1 |
20060212003 | Fangrow, Jr. | Sep 2006 | A1 |
20060212006 | Fangrow, Jr. | Sep 2006 | A1 |
20060224127 | Fangrow, Jr. | Oct 2006 | A1 |
20060264842 | Fangrow, Jr. | Nov 2006 | A1 |
20060264844 | Fangrow, Jr. | Nov 2006 | A1 |
20060264849 | Lopez et al. | Nov 2006 | A1 |
20060264909 | Fangrow, Jr. | Nov 2006 | A1 |
20060264910 | Fangrow, Jr. | Nov 2006 | A1 |
20060270999 | Fangrow, Jr. | Nov 2006 | A1 |
20060271016 | Fangrow, Jr. | Nov 2006 | A1 |
20060276757 | Fangrow, Jr. | Dec 2006 | A1 |
20060276758 | Fangrow, Jr. | Dec 2006 | A1 |
20070007478 | Leinsing et al. | Jan 2007 | A1 |
20070100284 | Leinsing et al. | May 2007 | A1 |
20070100295 | Belley et al. | May 2007 | A1 |
20070106205 | Connell et al. | May 2007 | A1 |
20070112312 | Fangrow, Jr. | May 2007 | A1 |
20070112313 | Fangrow, Jr. | May 2007 | A1 |
20070224865 | Fangrow, Jr. | Sep 2007 | A1 |
20070225425 | Nash et al. | Sep 2007 | A1 |
20070235676 | Vangsness et al. | Oct 2007 | A1 |
20070254000 | Guo et al. | Nov 2007 | A1 |
20070270756 | Peppel et al. | Nov 2007 | A1 |
20080039802 | Vangsness et al. | Feb 2008 | A1 |
20080086095 | Dikeman et al. | Apr 2008 | A1 |
20080086097 | Rasmussen et al. | Apr 2008 | A1 |
20080086099 | McKinnon et al. | Apr 2008 | A1 |
20080097407 | Plishka | Apr 2008 | A1 |
20080169444 | Guala | Jul 2008 | A1 |
20080249508 | Lopez et al. | Oct 2008 | A1 |
20090005761 | Guala | Jan 2009 | A1 |
20090209922 | Boisjoly | Aug 2009 | A1 |
20090292252 | Lareau et al. | Nov 2009 | A1 |
20090292274 | Guala | Nov 2009 | A1 |
20100030163 | Carrez et al. | Feb 2010 | A1 |
20100030164 | Kimball et al. | Feb 2010 | A1 |
20100036330 | Plishka et al. | Feb 2010 | A1 |
20100059474 | Brandenburger et al. | Mar 2010 | A1 |
20100059702 | Mansour et al. | Mar 2010 | A1 |
20100063456 | Rahimy et al. | Mar 2010 | A1 |
20100063482 | Mansour | Mar 2010 | A1 |
20100108681 | Jepson et al. | May 2010 | A1 |
20100152680 | Memahon | Jun 2010 | A1 |
20100174242 | Anderson et al. | Jul 2010 | A1 |
20100179514 | Guala | Jul 2010 | A1 |
20100241088 | Ranalletta et al. | Sep 2010 | A1 |
20100249724 | Cote, Sr. et al. | Sep 2010 | A1 |
20100249725 | Cote, Sr. et al. | Sep 2010 | A1 |
20100264343 | Jeory | Oct 2010 | A1 |
20100270792 | Lauer | Oct 2010 | A1 |
20100283238 | Deighan et al. | Nov 2010 | A1 |
20100292673 | Korogi et al. | Nov 2010 | A1 |
20100292674 | Jepson et al. | Nov 2010 | A1 |
20100300556 | Carmody et al. | Dec 2010 | A1 |
20100324502 | Guala | Dec 2010 | A1 |
20110004183 | Carrez et al. | Jan 2011 | A1 |
20110024664 | Burnard et al. | Feb 2011 | A1 |
20110028914 | Mansour et al. | Feb 2011 | A1 |
20110046572 | Fangrow | Feb 2011 | A1 |
20110048540 | Stroup | Mar 2011 | A1 |
20110054440 | Lewis | Mar 2011 | A1 |
20110060293 | Guala | Mar 2011 | A1 |
20110087164 | Mosler et al. | Apr 2011 | A1 |
20110106046 | Hiranuma et al. | May 2011 | A1 |
20110130717 | David et al. | Jun 2011 | A1 |
20110130724 | Mansour et al. | Jun 2011 | A1 |
20110130726 | Crawford et al. | Jun 2011 | A1 |
20110130727 | Crawford et al. | Jun 2011 | A1 |
20110130728 | McKinnon | Jun 2011 | A1 |
20110152832 | Foshee et al. | Jun 2011 | A1 |
20110166532 | Brandenburger et al. | Jul 2011 | A1 |
20110178493 | Okiyama | Jul 2011 | A1 |
20110257590 | Winsor et al. | Oct 2011 | A1 |
20110264037 | Foshee et al. | Oct 2011 | A1 |
20110266477 | Stroup | Nov 2011 | A1 |
20110275988 | Davis et al. | Nov 2011 | A1 |
20110276010 | Davis et al. | Nov 2011 | A1 |
20110276031 | Hoang et al. | Nov 2011 | A1 |
20110295235 | Fangrow | Dec 2011 | A1 |
20110306940 | Miyasaka | Dec 2011 | A1 |
20110319821 | Kitani et al. | Dec 2011 | A1 |
20110319859 | Zeytoonian et al. | Dec 2011 | A1 |
20120013121 | Weckstrom | Jan 2012 | A1 |
20120022469 | Alpert | Jan 2012 | A1 |
20120042971 | Py | Feb 2012 | A1 |
20120046636 | Kriheli | Feb 2012 | A1 |
20120053529 | Imai | Mar 2012 | A1 |
20120059314 | Eichhorst | Mar 2012 | A1 |
20120059334 | Pan | Mar 2012 | A1 |
20120059346 | Sheppard et al. | Mar 2012 | A1 |
20120095407 | Chebator et al. | Apr 2012 | A1 |
20120109077 | Ryan | May 2012 | A1 |
20120130352 | Naftalovitz et al. | May 2012 | A1 |
20120150129 | Jin et al. | Jun 2012 | A1 |
20120153201 | Larose et al. | Jun 2012 | A1 |
20120157928 | Mermet | Jun 2012 | A1 |
20120157933 | Newton et al. | Jun 2012 | A1 |
20120179108 | Delabie | Jul 2012 | A1 |
20120209238 | Rosenquist et al. | Aug 2012 | A1 |
20120215182 | Mansour et al. | Aug 2012 | A1 |
20120220955 | Maseda et al. | Aug 2012 | A1 |
20120220977 | Yow | Aug 2012 | A1 |
20120220984 | Christensen et al. | Aug 2012 | A1 |
20120245564 | Tekeste et al. | Sep 2012 | A1 |
20120259292 | Koehler | Oct 2012 | A1 |
20120316514 | Mansour | Dec 2012 | A1 |
20120316536 | Carrez et al. | Dec 2012 | A1 |
20120323063 | Costanzo | Dec 2012 | A1 |
20130030386 | Panian et al. | Jan 2013 | A1 |
20130035668 | Kitani et al. | Feb 2013 | A1 |
20130046315 | Woehr et al. | Feb 2013 | A1 |
20130053815 | Mucientes et al. | Feb 2013 | A1 |
20130060205 | Mansour et al. | Mar 2013 | A1 |
20130066293 | Garfield et al. | Mar 2013 | A1 |
20130079730 | Mosler et al. | Mar 2013 | A1 |
20130138075 | Lambert | May 2013 | A1 |
20130331800 | Newton et al. | Dec 2013 | A1 |
20140174578 | Bonnal et al. | Jun 2014 | A1 |
20140209197 | Carrez et al. | Jul 2014 | A1 |
20140316350 | Yamaguchi et al. | Oct 2014 | A1 |
20140358033 | Lynn | Dec 2014 | A1 |
20140371686 | Sano et al. | Dec 2014 | A1 |
20150008664 | Tachizaki | Jan 2015 | A1 |
20150148756 | Lynn | May 2015 | A1 |
20150151100 | Mansour | Jun 2015 | A1 |
20150190627 | Ueda et al. | Jul 2015 | A1 |
20150196749 | Ziv et al. | Jul 2015 | A1 |
20150265829 | Truitt et al. | Sep 2015 | A1 |
20150320992 | Bonnet et al. | Nov 2015 | A1 |
20160106970 | Fangrow | Apr 2016 | A1 |
20160114147 | Siopes et al. | Apr 2016 | A1 |
20160199575 | Belley et al. | Jul 2016 | A1 |
20160263369 | Naftalovitz et al. | Sep 2016 | A1 |
20170128710 | Fangrow | May 2017 | A1 |
Number | Date | Country |
---|---|---|
1 105 959 | Jul 1981 | CA |
2 149 725 | Nov 1995 | CA |
2 175 021 | Nov 1996 | CA |
636526 | Jun 1983 | CH |
670955 | Jul 1989 | CH |
855 319 | Sep 1952 | DE |
84 25 197.2 | Sep 1985 | DE |
37 40 269 | Jun 1989 | DE |
0 263 789 | Apr 1988 | EP |
0 309 771 | Apr 1989 | EP |
0 399 119 | Nov 1990 | EP |
0 446 463 | Sep 1991 | EP |
0 805 930 | Jun 2002 | EP |
1 547 646 | Jun 2005 | EP |
1 563 867 | Aug 2005 | EP |
1 854 502 | Nov 2007 | EP |
1 857 137 | Nov 2007 | EP |
1 669 101 | Jul 2008 | EP |
2 707 505 | Jan 1995 | FR |
2 000 685 | Jan 1979 | GB |
2 001 146 | Jan 1979 | GB |
2 034 185 | Jun 1980 | GB |
333508 | Aug 2005 | NZ |
WO 199220736 | Nov 1992 | WO |
WO 199422523 | Oct 1994 | WO |
WO 199623158 | Jan 1996 | WO |
WO 199959672 | Nov 1999 | WO |
WO 199961093 | Dec 1999 | WO |
WO 2003018104 | Mar 2003 | WO |
WO 2005115521 | Aug 2005 | WO |
WO 2006013433 | Feb 2006 | WO |
WO 2006062912 | Jun 2006 | WO |
WO 2007112278 | Oct 2007 | WO |
WO 2008048777 | Apr 2008 | WO |
WO 2009052433 | Apr 2009 | WO |
WO 2009111596 | Sep 2009 | WO |
WO 2010135080 | Nov 2010 | WO |
WO 2011064738 | Jun 2011 | WO |
WO 2011101389 | Aug 2011 | WO |
Entry |
---|
Reexamination proceedings for U.S. Pat. No. 5,730,418 (Reexamination Control No. 90/006,177) including the amendments filed by the owner ofthe patent during reexamination proceedings. |
U.S. Appl. No. 14/996,564, filed Jan. 15, 2016, Fangrow. |
CardinalHealth, SmartSite Brochure: “SmartSite® Disposables,” 2004, in 12 pages. |
“Faulding Inc. receives FDA permission to market patented Safe-Connect Valve”, dated Dec. 2, 1996. |
BD Medical: Needleless IV Access Devices, one page, 2007. |
Capless Backcheck Valve, dated Sep. 3, 1993. |
CareFusion, Medegen Introduces MaxPlus® Clear, First and Only Clear Positive Displacement Connector for Use in Infusion Therapy, MaxGuard News, one page article, dated Mar. 10, 2008—Ontario, CA. |
Caresite™ Luer Access Device, dated 2010. |
Clearlink, needleless IV access system, Baxter 2007 brochure in 2 pages. |
F.D.A. 510(k) Summary of Safety and Effectiveness, dated Nov. 17, 1997. |
LifeShield TKO Anti-Reflux Device Brochure, appears to contain a date of Feb. 8. |
MEDI-4955 Liquid Silicone Rubber from NuSil Silicone Technology, dated Dec. 17, 2010. |
MicroClave Connector Brochure. The MicroClave was available before Mar. 25, 2008. |
MicroClave Neutral Displacement Connector A Neddlefree Closed System Device. Brochure Sep. 24, 2008. |
MicroClave Product Page Video Shots. Sep. 24, 2008. |
Nexus Medical Nexus TKO, appears to contain a date of Mar. 2006. |
PASV Valve Connector Brochure, which appears to be at least as early as Feb. 20, 2001. |
Photographs of LifeShield Clave® & TKO-4S product, consisting of a needleless valve essentially as illustrated in Lopez (U.S. Pat. No. 5,685,866) and a flow control valve essentially as illustrated in Dikeman (U.S. Pat. No. 7,601,141), sold in the U.S. at least as early as May 2008. |
Saechtling Tworzywa Sztuczne, WN-T Warszawa, 1999, V edition, pp. 224-225. |
Number | Date | Country | |
---|---|---|---|
20180050184 A1 | Feb 2018 | US |
Number | Date | Country | |
---|---|---|---|
61345554 | May 2010 | US | |
61392426 | Oct 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14961163 | Dec 2015 | US |
Child | 15693853 | US | |
Parent | 14520240 | Oct 2014 | US |
Child | 14961163 | US | |
Parent | 14309489 | Jun 2014 | US |
Child | 14520240 | US | |
Parent | 13106781 | May 2011 | US |
Child | 14309489 | US |